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ABSTRACT
Metabolomics is a burgeoning field that involves the detection of a great variety of
compounds which are present in several matrices, including cells, tissues or biofluids. As
metabolites are end products of the biochemical pathways, alterations in their levels
reflect alterations in the normal function of the organism. Therefore, metabolomics has
been implemented in several clinical areas, mainly because a particular disease or
pathological condition may present a unique metabolic profile. This is of major importance
for disease diagnosis, prognosis and monitoring. Additionally, metabolite levels can be
measured through analysis of urine or blood, whose collection is less invasive than
biopsies. Despite its endless applications, metabolomics has shown to be particularly
useful in the search of diagnosis cancer biomarkers. Its application in cancer research
relies on the fact that cancer cells suffer a metabolic reprogramming to balance their
energetic needs to support the rapid tumour growth. Indeed, there are several
metabolomic studies reporting alterations in metabolites levels in many types of cancers,
namely bladder cancer (BC). BC is one of the most common and fatal malignancies of the
urinary system, whose incidence continues to rise. Current diagnosis methods are
extremely invasive and poor sensitive. Thus, they often detect BC at advanced stages
where prognosis is dismal and the probability of treatment success and patients’ survival
rate are low. For these reasons, it is evident the necessity in identifying new biomarkers
and to develop earlier diagnosis strategies.
The work presented in this thesis provides a proof-of-concept for the in vitro
prediction of BC from volatile organic compounds (VOCs) analysis of the extracellular
medium of bladder cells (both cancer and normal), using Headspace-Solid Phase
Microextraction/Gas Chromatography-Mass Spectrometry (HS-SPME/GC-MS) technique.
Aiming at the investigation of the potential of volatiles as new biomarkers for BC detection,
as well as for the classification of the disease according to histological grade and subtype,
this study comprised the analysis of three bladder cancer cell lines (5637, J82 and
Scaber) and one normal cell line (SV-HUC-1). Two different pHs (pH 2 and pH 7) were
also evaluated in order to determine the best pH for VOCs extraction to be used in future
in vitro metabolomic studies. After statistical analysis, it was observed that VOCs collected
from the bladder cells exometabolome, at both pHs, enable the separation of BC cell lines
from the normal one, as well as the discrimination between low-grade and high-grade BC
and between two different BC histological subtypes. These results are encouraging as
they demonstrate the biomarker potential of volatiles for BC diagnosis. Nevertheless, the
metabolic pathways that lead to VOCs production are not yet deeply elucidated, hindering
xa complete comprehensive interpretation of the results. Therefore, validation studies and
application of the method to clinical samples (particularly urine) from BC patients are
required not only to improve knowledge about VOCs metabolism, but also to evaluate and
confirm the translatability of these VOCs to clinical practice.
Keywords: Bladder cancer (BC); Metabolomics; Volatile Organic Compounds (VOCs);
Biomarkers; HS-SPME/GC-MS
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RESUMO
A metabolómica é uma área da ciência que tem crescido exponencialmente, e que
envolve a deteção de uma grande variedade de compostos presentes em várias matrizes,
incluindo células, tecidos ou fluídos biológicos. Sendo os metabolitos produtos finais das
vias metabólicas, alterações nos seus níveis refletem alterações no normal
funcionamento do organismo. Assim, a metabolómica tem sido implementada em várias
áreas da biomedicina, principalmente porque uma determinada doença ou condição
patológica podem apresentar um perfil metabólico específico. Isto é bastante importante
na medida em que pode ajudar no prognóstico, diagnóstico e monitorização de doenças.
Além disso, os níveis dos metabolitos podem ser avaliados através da análise de urina ou
sangue, cuja recolha é menos invasiva do que as biópsias. Apesar das suas infinitas
aplicações, a metabolómica tem demostrado ser útil na procura de biomarcadores de
diagnóstico de cancro. A sua aplicação na oncologia assenta no facto das células
cancerígenas sofrerem uma reprogramação metabólica de forma a equilibrarem as suas
necessidades energéticas, para, assim, manterem o rápido crescimento do tumor. De
facto, já existem bastantes estudos metabolómicos que revelam alterações nos níveis de
metabolitos em vários tipos de cancro, nomeadamente o cancro da bexiga. Este cancro é
uma das neoplasias mais comuns e fatais do trato urinário, cuja incidência continua a
aumentar. Os métodos de diagnóstico atuais são extremamente invasivos e pouco
sensíveis. Por isso, o cancro da bexiga é, na maioria das vezes, diagnosticado em
estádios já avançados, cujo prognóstico é péssimo, sendo baixos a probabilidade de um
tratamento ter sucesso e o tempo de sobrevivência dos doentes. Por estas razões, há
uma necessidade evidente em identificar novos biomarcadores e em desenvolver
métodos que permitam o diagnóstico mais precoce do cancro em questão.
O trabalho apresentado nesta tese permite obter uma “prova de conceito” para o
diagnóstico in vitro do cancro da bexiga, através da análise de compostos orgânicos
voláteis (COVs) do meio extracelular de células da bexiga (tanto cancerígenas como
normais), usando a técnica da microextração em fase sólida no headspace (HS-SPME)
seguida de cromatografia gasosa acoplada à espetrometria de massa (GC-MS). Com o
objetivo de investigar potenciais voláteis como novos biomarcadores de diagnóstico do
cancro da bexiga, bem como a classificação deste cancro de acordo com o grau e
subtipo, este estudo incluiu a análise de três linhas de bexiga cancerígenas (5637, J82 e
Scaber) e uma linha celular normal (SV-HUC-1). Foram avaliados dois pHs diferentes (pH
2 e pH 7) para determinar qual deles seria o melhor para a extração de voláteis, de forma
a ser aplicado em estudos in vitro metabolómicos futuros. Depois de ser feita uma análise
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estatística dos resultados, observou-se que os voláteis extraídos do exometaboloma das
células da bexiga, em ambos os pHs, permitiram a separação das linhas cancerígenas da
linha normal, bem como a discriminação entre cancro de baixo e alto grau e entre dois
subtipos diferentes de cancro da bexiga. Estes resultados são promissores na medida em
que mostram o potencial dos voláteis como biomarcadores de diagnóstico deste cancro.
Contudo, as vias metabólicas que levam à produção de COVs ainda não estão totalmente
compreendidas, impedindo uma interpretação mais precisa dos resultados. Portanto, são
precisos mais estudos para a validação dos COVs e aplicação deste método em
amostras biológicas (particularmente urina) de doentes com cancro da bexiga para não
só melhorar o nosso conhecimento sobre o metabolismo dos COVs, mas também para
avaliar e confirmar a translação dos mesmos para a clínica.
Palavras-chave: Cancro da bexiga; metabolómica; compostos orgânicos voláteis
(COVs); biomarcadores; HS-SPME/GC-MS
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1. INTRODUCTION TO METABOLOMICS
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1.1. Definition and metabolomics workflow
Metabolomics is the most recent “omic” science (1, 2) that arises as a
complementary tool for genomics and proteomics. These two-last mentioned “omic”
sciences are not yet fully understood and none of them considers the cellular activity at a
metabolic level, a fact that is overcome through metabolomics. Therefore, metabolomics
is the study of biochemical and biological processes that involve metabolites, the end
products derived from cellular activity, which constitute the metabolome of an organism
(3). Basically, it studies metabolite profiles consisting in unique and specific chemical
features that represent the last biological reaction or response to a certain stimulus (4, 5).
Metabolomics relies on the fact that any alteration in the normal functioning of systems
biology caused by, for instance, the development of certain pathologies, affects the
system homeostasis. Hence, metabolomics can provide detailed information on the
physiological status of an organism, organ, cell or even a subcellular compartment (for
instance, the mitochondria) (4), whether it is altered or not, through metabolite imbalances
or stress (6). Metabolomics is also frequently named by a similar term, “metabonomics”
(2, 7), which is not completely correct since metabonomics is seen as a more dynamic
measure of metabolic responses to pathophysiological stimuli, genetic modification or
response to diseases, drugs, toxins, and other adversities (8). On the other hand,
metabolomics provides a comprehensive analysis of the entire metabolome through
identification and quantification of all metabolites.
Metabolomic approaches can be classified as targeted or untargeted. In targeted
metabolomics, specific well-known metabolites or a group of metabolites biochemically
related are evaluated qualitatively and quantitatively (9, 10). On the contrary, untargeted
metabolomics consists in the analysis and measurement of all possible metabolites
present in a given biological system, and comparison between classes of samples (9),
giving the opportunity to explore and discover new biochemical features and pathways.
Independently of the approach, the main goal of metabolomic studies is the detection of a
great number of metabolites without the requisite of exhaustive sample preparation (11).
Several studies have provided insight into how metabolomics can be useful in
different fields of investigation (6, 10, 12-15), such as in the pharmaceutical and
biotechnological fields (4, 7, 16, 17), and clinical medicine, particularly in areas such as
biomarker discovery for disease diagnosis, prognosis, staging and treatment selection,
drug development, monitoring therapies and evaluation of treatments effectiveness at
earlier stages of a malignancy (4, 9, 18-24). From a therapeutic perspective,
metabolomics is also useful for the development of biomarkers that provide information on
4how different individuals will respond to drugs or to certain treatments (6). Particularly in
cancer, metabolomics can be applied in the development of new diagnosis methods
through the identification of biomarkers that might enable early diagnosis, monitoring of
disease progression, prognosis, treatment guidance, drug discovery and development of
new therapies (25, 26). The development of new biomarkers might overcome the
limitations of classical diagnostic methods, since these often detect a malignancy in a
rather late stage, where, in most cases, therapeutic possibilities and survival rates are
lower (6). Furthermore, in cancer therapies, metabolomics can be applied in the
monitoring of radiotherapy (27).
The potential of metabolomics and its several applications in oncology has
increased. Indeed, metabolomics applied to cancer research has grown exponentially in
the last decade, owing mainly to the discovery that cancer cells present an altered
metabolism compared to normal cells (6, 28). In fact, it is well-known that cancer cells
have greater energetic needs for growth, proliferation and survival, known as the
“Warburg effect” (29, 30). Noteworthy, some studies have shown that oncogenes can
interfere with metabolism (28, 31) and, in turn, alterations in the metabolism can cause
mutation and activation of oncogenes (32). This highlights the importance of monitoring
metabolic changes as it might help in both cancer detection and the comprehension of its
mechanisms (33). Early diagnosis is one of the main goals of cancer metabolomics since
in some cancers, such as bladder cancer, early detection and screening is still insufficient
by the classical methods. Along with the development of metabolomics and its application
in cancer research, a new concept has emerged: the cancer metabolome, which includes
metabolites potentially suitable as biomarkers and particularly relevant to both oncologic
processes and systemic responses to the malignancies (34).
Metabolomic studies have been performed in a wide range of samples, from cells
in vitro (35-39) to tissues (20, 21, 40-43) or biofluids (22, 44-51), as well as hair (52),
breath (15) and faeces (53, 54), which can be analysed through NMR or MS-techniques.
The main steps of a metabolomic study include sample collection and preparation, data
acquisition, statistical analysis and interpretation, as illustrated in figure 1. Each step will
be described in more detail in the following topics.
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Figure 1. Schematic representation of the general workflow of metabolomics studies.
1.2. Samples Collection, Storage and Preparation
The most used biological model systems in metabolomic studies include in vitro
cancer cultured cells, ex vivo cancer tissues and human biofluids, more commonly urine
and serum (26). In any metabolomic study, the first step involves sample collection,
storage and preparation (44), important procedures that will determine the integrity and
successfulness of the metabolic analysis (55). Ideally, samples should be analysed
without any preparation steps, since they might lead to the appearance of contaminants or
some metabolites, or loss of others (56). Since that is not possible, it becomes crucial to
ensure that samples are handled, stored and prepared appropriately and uniformly to
avoid biased analysis and to allow the direct comparison between samples in terms of
metabolites composition (10). Also, the collection and storage conditions are critical for
protecting the metabolites from degradation or inhibiting the appearance of other foreign
metabolites (for example, due to bacterial activity, especially in urine) (56, 57) that would
contaminate the samples and render them unviable.
Factors such as age, gender, ethnic origin, diet, fasting state, life-style (smoking,
drug or alcohol abuse), physical activity, diseases, and time of the day of sample
collection should be taken into account in order to minimize their effects on the
6metabolomic results (55). Therefore, it might be also important to collect information from
the subjects/patients because it can aid in the interpretation of the results. Recruitment of
best matched control populations is mandatory to reduce possible variations that arise
from the factors mentioned above.
1.2.1. Collection and Storage of samples
Handling conditions depend on the type of matrix that will be analysed. Tissue
samples collection require immediate inhibition of the metabolism to avoid the induction of
“stress” metabolites (from hypoxia, for instance). The most common and sufficient method
is to snap-freeze tissues in liquid nitrogen (55, 58).
As for serum or plasma, the first one is obtained by removing the natural clot from
the blood, and the second one is the supernatant phase obtained by mixing blood with an
anticoagulant, followed by a swift centrifugation at 4ºC (58). Lithium heparin is the most
preferred anticoagulant in a metabolomic study since it does not interfere with the
metabolic screening and profiling, unlike EDTA, for instance (58). After collection, samples
must me immediately processed and stored in sterile containers at or below -70ºC (55,
56).
Regarding urine, its composition presents a diurnal variation that affects the time of
collection (59), unlike other samples. As there is no standard method for urine collection
and handling in metabolomics (44), it is of utmost importance to ensure that its collection
and manipulation is uniform to avoid discrepancies. There are three different techniques
for collecting urine samples: spot urine, which is collected at the time of a medical
consultation (58); timed urine samples, used when studying time-related variations,
especially in metabolites with high diurnal alteration (60); and 24h sample collection,
which consists in collecting all urine produced within a day (61). The main disadvantage of
spot urine is the variation in metabolites composition due to diet, circadian rhythm or
lifestyle factors, which the 24h or first-pass urine collection may minimize (58). However, it
has been reported that variations caused by pathologies are more significant that those
caused by sample collection (62). It was also demonstrated that there is no significant
difference, in terms of metabolic profile, between urine samples that are immediately
frozen from those stored initially at 4ºC for 24h (63). Other studies have shown that urine
samples are stable up to 6 months, either at -20 or -80ºC, and after multiple freeze-thaw
cycles (until nine cycles) (62, 64). The method of freeze-drying has proven to cause
instability of the urinary metabolites (64). Moreover, it was demonstrated that it is not
obligatory to add a preservative in urine samples stored at below -20ºC (64).
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Another characteristic of urine is the high abundance in urea that can hinder the
detection of metabolites that co-elute with urea intense peak (65). Adding urease to urine
samples to remove urea seemed to be a solution; however, it was shown that urease can
also interfere with the identification of some metabolites (66). To overcome this problem,
there is the possibility of optimizing the chromatographic parameters, for instance, so that
co-elution is withdrawn (65). Bacterial activity is also a drawback when working with urine,
being common the addition of sodium azide to inhibit it, without interfering with the stability
of the samples (59).
Lastly, cell culture model systems, which are divided into primary cell culture, cell
lines and cell strains, present a different collection approach, which depends on whether
they grow adherently to an inert surface or in suspension in a liquid medium (67). In the
case of suspension culture, cells can be collected from the medium through centrifugation
(68) or filtration (69). Subsequently, to obtain the metabolic profile, quenching (responsible
for inhibiting all cellular activities that might contribute to metabolic changes (67)) and
extraction protocols are applied. The most recommended quenching technique is the use
of cold (0.5ºC) isotonic saline (0.9% w/v NaCl), since it proved to be non-destructive and
effective in inhibiting ADP and AMP generation from ATP (70). As for the extraction step,
it was shown that using cold 50% aqueous acetonitrile provided a greater metabolite
recovery and concentration (70). In turn, adherent cells require an additional first step
before quenching and metabolite extraction, namely their harvesting from the culture
flasks that can be achieved by trypsinisation or cell scrapping (67). Nevertheless, trypsin
method has proven to be less suitable for in vitro metabolomics since it might cause
membrane damage and metabolite loss, and consequently, lead to poorer metabolite
content (71). Therefore, cell scrapping seems to be the best method, particularly when
performed in an extraction solvent so that cell quenching is simultaneous. Among the
possible extraction solvents, cold 80% methanol showed the highest extraction efficiency
and reproducibility (72).
Independently of the type of culture (suspension or adherent cells), the
standardization of culture conditions is crucial to better control the cell growth rate and
phenotype stability so that reproducibility of the metabolomic data is higher (73). Indeed,
any discrepancies in the number of harvested cells will lead to incorrect interpretation of
the metabolomic results. Another important factor is the culture medium because it
determines the cell growth and any variation in its composition will result in different
consumption rates of substrates, affecting the cells metabolic profile (70, 73). Hence, it is
recommended the use of the same medium in all experiments to avoid variations, even
when dealing with different cell types. Nevertheless, the use of the same culture medium
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8is not always possible, when different cell lines only grow in different optimal medium.
Otherwise, cells would grow inadequately or die (73).
For all sample types, it is recommended the storage in multiple aliquots post
collection to avoid sample loss and degradation from various freeze/thaw cycles in a
multiple metabolomic analysis (58, 63).
1.2.2. Sample treatment
Sample preparation involves several steps, such as extractions or use of buffers,
which must be consistent and standardized as much as possible (55). Methods such as
protein precipitation or metabolite extraction are widely used to reduce the interference of
unwanted compounds (56). Nevertheless, there is not a protocol that solely covers the
total metabolome (56). Therefore, it is becoming more common the performance of
different extraction methods that, when combined, result in a larger number of
metabolites.
1.3. Data acquisition
1.3.1. Analytical techniques
There are different analytical platforms that can be employed in a metabolomic
study, each one presenting their advantages and limitations. When choosing which
equipment to use, several factors must be considered, namely the aims of the study, the
nature of the samples and the compounds that will be analysed, and also the financial
capacity of the laboratory (56). The most widely employed analytical tools are nuclear
magnetic resonance (NMR) spectroscopy and mass spectrometry (MS)–based techniques
(2, 56). Once again, there is not a single platform that covers the entire metabolome,
which is why it is desirable to combine them in order to obtain more information.
1.3.1.1. Separation techniques
In metabolomics, the separation of the analytes is generally by chromatographic
methods, although electrophoresis (especially capillary electrophoresis) can also be
applied (2).
The most widely used technique is gas chromatography (GC), which is usually
coupled with mass spectrometry (GC-MS). GC advantage is its high chromatographic
resolution; however, only volatile compounds (low molecular weight compounds) can be
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analysed or those that can be volatilized. Other biomolecules, that are non-volatile and
thermally labile, cannot be analysed unless they go through derivatization processes (2,
56). On the other hand, liquid chromatography (LC), also commonly coupled with MS, or
high performance liquid chromatography (HPLC) have a lower chromatographic resolution
and matrix effects are still challenging but, unlike GC, they can be used for a wider range
of compounds (2), requiring lower amounts of sample, and derivatization steps are not
needed (58).
1.3.1.2. Detection techniques
NMR provides detailed information on the structure of the analytes (56); it is non-
discriminating, since it can detect all compounds with a resonating nuclei (e.g., 1H, 13C,
15N) and non-destructive, since sample preparation is easy and minimal (6, 26, 56),
allowing the recovery of sample for other analysis (2). Besides, it can analyse either liquid
or solid samples, such as integral tissues or cell extracts (11, 26), presenting high
reproducibility and resolution (6, 26, 56). The main disadvantage of NMR is its relatively
lower sensitivity compared to MS (2, 74) and requires large amounts of sample (56).
Other limitations include more expensive acquisition and maintenance, the special training
needed to use NMR and the fact that it is not commonly used in clinics (6, 74).
The MS-techniques are used to identify and to quantify analytes after their
separation by GC or LC (2), despite quantification is more difficult in MS than in NMR (6).
MS is both sensitive and very specific (2, 6), and the separation of complex mixtures is
more efficient (56). It has a high resolution, but the reproducibility is low, especially for
biofluids (6). Additionally, it is more widely used in clinics than NMR (74). The major
drawback of MS-techniques is the time-consuming sample preparation before analysis (6,
26, 56), such as derivatization, that can lead to sample alteration and, consequently, to
inaccurate conclusions.
1.3.2. Quality control (QC)
In any metabolomic study, it is important to include quality control (QC) samples to
ensure that the detection of metabolite differences among samples is not hindered by
undesired sources of instrumental deviations, such as contamination peaks (2, 73). When
planning a metabolomic experiment, it should be included enough QC samples from each
population, so that it is possible to achieve metabolites validation and to minimize the
probability of false results. Thus, the purposes of these samples, together with
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standardization, is to ensure and optimize the reliability and reproducibility of the data
obtained during metabolomic analysis, to determine the analytical precision and provide
the possibility of performing signal correction so that signal variations are minimal (73, 75).
QCs are also useful to evaluate the quality of samples, whether they are degraded or
contaminated, which will affect the results (59). There are four main types of QCs that can
be employed in a metabolomic study (55):
a) Chemical shift standards, namely 4,4-dimethyl-4-silapentane-1-sulfonic acid
(DSS) or 3-(trimethylsilyl)propionic acid (TSP), or pH standards (e.g., imidazole)
for NMR analysis; in case of quantitative MS analysis, it is recommended
leucine-enkephalin or labeled reference chemical standards;
b) Synthetic sample of around 30 to 40 representative compounds in biofluids or
tissue metabolomic analysis, also useful in intra-lab quality control;
c) Pooled samples from the study, useful to correct batch effects, particularly in
studies with high volume of samples;
d) Pooled human blood and urine standard reference materials (SMR) from the
National Institute of Standards and Technology (NIST), which is available to all
laboratories worldwide, being useful for inter-lab quality control.
1.4. Bioinformatics and statistical analysis
When performing an untargeted metabolomic study, rather than a targeted
approach, the amount of data is immense, making difficult to analyse it without specialized
software. After collecting the data, and before the statistical analysis, NMR or MS spectra
need to be corrected to lessen the variations caused by experimental factors (56), such as
those inherent to the analytical platforms (e.g., day-to-day alterations in sensitivity) or
during sample preparation. Thus, metabolomics data need to be processed and
normalized, a step that includes peak normalization and alignment, baseline correction,
noise reduction, and deconvolution of peaks (important in cases of co-elution of
compounds) (10, 58). Nowadays, these processes can be achieved more rapidly owing to
the several bioinformatics software available (MZMine, XCMS, and others) (56, 58).
Furthermore, in in vitro metabolomic studies, some additional and particular normalization
methods are used to determine the cellular density, because it affects the metabolite
concentration. Only then it is possible to compare the metabolite profile among samples of
highly proliferative cells (67, 73). These methods include cell counting, protein or DNA
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quantification, total metabolite signal or specific metabolic markers, being the DNA
quantification the most robust strategy due to its higher accuracy and consistency of the
measurements (73, 76).
After data pre-processing, which yields a great number of challenging variables to
interpret (58), statistical analysis takes place. Multivariate statistical techniques can be
classified into unsupervised or supervised. In the unsupervised approaches, no
information is provided regarding samples classification so that they are separated
according to their metabolite composition, leading to a prompt identification of possible
similarities or differences between samples and also to the detection of outliers (11, 77).
Principal component analysis (PCA) is the most commonly used unsupervised method
and usually performed first. Subsequently, supervised approaches are applied, such as
partial least squares-discriminate analysis (PLS-DA) or orthogonal PLS-DA (OPLS-DA)
(77). In these methods, prior information on sample classes is given and they are mainly
used to uncover the discriminative features between different classes of samples (26, 77).
Once the potential metabolic signatures are identified as discriminative biomarkers, the
metabolites must be identified. This part of a metabolomic study can be challenging since
most spectral peaks can be unknown. Nevertheless, several metabolomics databases (2,
56, 58), such as the Human Metabolome Database (HMDB) or METLIN, can be helpful
when identifying the peaks. However, for a more accurate identification, it is
recommended to use standards of the respective analytes (2).
After the identification of potential metabolomic biomarkers, it is important to evaluate
their functional and biological relevance with, for instance, metabolic pathway analysis.
There are also tools available that provide remarkable representations of countless
pathways (58), such as the Kyoto Encyclopaedia of Genes and Genomes (KEGG)
database. Finally, additional studies must be performed to test and validate the potential
metabolites (2) so that they become relevant as diagnostic or prognostic biomarkers.
Validation studies are, generally, performed using larger and biologically diversified
independent sample sets that highly represent the human population of interest. The main
purposes of these studies are to check whether a biomarker or panel of biomarkers are
associated with a disease and how accurate and specific on they are, so that its
application in clinical research is enabled (78-80).
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1.5. General challenges and limitations of metabolomics
The full employment of metabolomics in clinical practice is still challenging, despite
the progresses and efforts in the search of biomarkers that could improve early diagnosis
of diseases, especially in cancer.
Firstly, it is difficult to deal with the complexity and heterogeneity of the human
metabolome, because of the high number of classes of compounds (peptides, amino
acids, carbohydrates, organic acids), and the wide range of interactions and biological
pathways in which they are involved (81). It would be necessary the combination of
several analytical platforms to cover the whole metabolome (81). Still, even with only one
analytical tool, the amount of data generated is great and complex enough to make it
difficult to interpret without the application of very powerful bioinformatic tools (11, 56), as
described previously. Likewise, there is the complexity and heterogeneity inherent to
samples (whether they are biofluids or tissues) and patients, which are associated with
several confounding factors such as age, gender, genetic background, lifestyle factors,
diet, presence of other pathological conditions and respective therapies, surgical
intervention (58, 82), and even metabolites derived from bacterial metabolism, a particular
problem in urine samples (56). Consequently, this leads to “metabolic variability” (83) and
false results, highlighting the importance of eliminating the confounding factors as much
as possible. Hence, to overcome those confounding factors it is essential the inclusion of,
besides healthy controls (HCs), symptomatic controls (SCs) (84), which consist of a group
of patients that manifest the same symptoms as those with the disease of interest, but
they do not present any clinical findings of that disease whatsoever, at the time of
sampling (85).
Furthermore, in different studies that focus on the same disease (for example,
bladder cancer) aiming at the discovery of novel diagnosis biomarkers, there is relatively
little overlap between the identified metabolites, even when the same specimens were
analysed (21, 22, 41, 46, 86-90). These inconsistencies are likely due to diverse sample
collection and manipulation, work environment conditions, different planning and study
design and the use of different analytical techniques. Thus, it is evident the lack of
standardization methods when performing a metabolomic study. Besides, it is evident the
insufficiency of the sample’s size (either of disease or healthy controls) among studies as
well, which lessens the reliability and the importance of the results.
Moreover, most studies do not test if metabolites found result from systemic
responses to cancer or are actually produced by cancer cells. This is particularly important
in in vitro studies, where the cancer-host interactions are lost (91, 92), as well as the
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environment created within and around the tumour. These might explain the discrepancies
of the results observed in in vitro studies and studies using tissues or biofluids. Besides,
the confounding factors, that cause metabolomic variability, do not affect in vitro studies,
which may be considered a benefit or a drawback, especially in the translatability to clinics
since genetic and biological factors can influence the diseases outcome and progression,
particularly cancer. Thus, although in vitro models are not as complex as the other
matrices and show potential in helping the discovery of putative biomarkers, the
interpretation of the results must be cautious and rigorous. The same applies when
dealing with animal model systems, because of the inter-species genetic and metabolic
differences, or human samples, due to inter- and intra-variability. In fact, a multiple matrix
metabolomics study using human tissue and biofluids would be interesting to improve the
comparison of the results and unveil which sample type is a better proxy of a certain
disease.
It is crucial to carefully reflect on all those factors, because the interpretation of
validation assays depends on it. Evaluation and validation studies are the most difficult
step in a metabolomic experiment, besides being expensive, and time and sample
consuming; however, they are necessary to enable the translation of the biomarkers found
into clinical practice (83).
In cancer metabolomic studies, another setback must be taken into account, which is
the fact that most metabolic alterations are common among various cancer types.
Therefore, in these cases, validation studies of potential biomarkers should include other
malignancies to better evaluate their specificity. Still concerning this setback, overcoming
it might go through the determination and consideration of a panel of biomarkers rather
than a single one (93-96).
1.6. Particularities of in vitro metabolomics for VOCs analysis
Volatile organic compounds (VOCs) are carbon-based molecules that present high
vapour pressure at room temperature. They are classified according to their molecular
weight and boiling point (50ºC - 260ºC) (97). Organisms can produce and release these
compounds in exhaled breath or through body fluids such as urine, blood, sweat or faeces
(53, 98-100), which in turn can be collected from the headspace (HS) of those matrices. In
the case of in vitro studies, VOCs can also be collected from the HS of cells’ extracellular
medium (39).
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The curiosity to investigate volatiles and their potential as diagnosis biomarkers has
started with the observation that distinct diseases can be characterized by urine, exhaled
breath or sweat specific odours (101), which are correlated with different VOCs patterns.
Particularly for cancer, it was demonstrated that dogs can be trained to diagnose bladder
(102), colorectal (103), lung and breast cancers (104) and melanoma (105) by sensing
patients, supporting the idea that different diseases do have a characteristic “smellprint”
(106). Therefore, there has been a great interest to study the cancer volatilome and a
great attempt to discover VOCs as potential biomarkers for disease diagnosis (39, 53, 98,
103, 107-111). This new approach relies on the fact that VOCs are final products of
cellular metabolism (106) and they are released through cell membranes, such as
phospholipids or carbohydrates. Consumption or release of specific VOCs depends on
cell membranes composition, which vary according to gene and/or protein characteristics
(112), or if affected by oxidative stress and lipid peroxidation that cause membrane
modification (106). Evidently, tumour cells will emanate a distinct pattern of VOCs due to
their genetic alterations or protein modifications that affect oxidative stress and
consequent peroxidation of membrane components (106).
The analysis of VOCs presents several advantages including simple and fast
sample preparation, compared to other molecules that need a derivatization process (e.g.
amino acids and fatty acids), which prevents loss of metabolites; non-invasive collection
(easily detected in exhaled breath or urine); enables high-throughput screening and
analysis of numerous compounds across different samples (113). Considering in vitro
VOCs collection, this approach may help to understand the source of VOCs as cell
metabolomics present more controllable experiment designs and easier interpretation of
the results due to the absence of factors related to age, gender and other individual
differences that affect the metabolic profile (73).
When performing an in vitro metabolomic study, the whole cell metabolome can be
investigated or instead, either the endometabolome, which comprises all metabolites
present inside the cell, or the exometabolome, which is represented by all metabolites in
the cell extracellular culture medium (73, 97). The exometabolome profile results from the
interchange of compounds between cells and the culture medium. This will reflect cells
metabolism, which differs if variations in the culture medium or in the experimental design
are introduced (73). The study of the exometabolome is highly favoured over the
endometabolome in VOC-biomarker investigations due to the fact that endometabolomic
approaches require additional cell membranes disruption and concentration of the
collected compounds, which can lead to a substantial loss of VOCs (73).
15
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In in vitro studies, two main matrices are used for VOCs collection, namely the
headspace (HS) of cell-free culture medium or HS of medium containing cells (97). These
two approaches present some differences in the extraction procedures, such as the
temperature of the analysis, which is 37 ºC in the presence of cells but higher in cell-free
culture medium; the addition of salts or alteration of the pH in cell-free culture medium to
improve the efficiency of the analysis, which cannot be employed in the presence of cells.
In contrast, analysing medium samples with cells avoids the loss of VOCs during storage
(97, 114). Regarding the techniques used to collect VOCs, some enhancements have
been made over the years to improve sample preparation and VOCs extraction
methodologies. Among the possible techniques that can be employed, solid-phase
microextraction (SPME) is one of the best options as it provides a simple, economical,
solvent-free, low time-consuming method for VOC extraction, sample pre-concentration
and analysis, enabling minimal sample treatment and, consequently, minimal alteration of
sample metabolites (115, 116). An analogous technique is headspace-SPME (HS-SPME),
in which compounds present in the gas space are analysed, and their adsorption to the
SPME fibre depends on the equilibrium between the sample and the HS, as well as
between the HS and the fibre coating. The efficiency of HS-SPME depends on several
factors including the chemical nature of the compounds (volatiles or easily volatilized), the
type of fibre coating, extraction temperature and time, salting-out effect and the type of
sample (whether it is biological, or in solid, liquid or gas phase) (117, 118). Nowadays, it is
widely used HS-SPME coupled with GC-MS because it allows a rapid, efficient and
automated VOCs extraction followed by immediate identification.
The limitations related to general metabolomic studies in terms of lack of
standardized extraction and analytical methods also include in vitro VOCs studies, which
hampers the possibility to compare results among different studies. Other aspects of in
vitro approaches that contribute for the discrepancies found among cell metabolomic
studies include the use of different cell types and cell culture medium, different cell
controls, different cell density and period of cultivation and growth, and different
methodology for collection, handling and storage of culture medium samples (97). Another
possible limitation of in vitro VOC studies is that the metabolites found altered in cancer
cell lines and considered potential biomarkers may not be found in in vivo or ex vivo
analysis. It has been proposed that hyperoxic cell culture conditions lead to those
divergences since cancer tissues are associated with hypoxic (low oxygen) or anoxic
(absence of oxygen) growth conditions, in contrary to normal tissues (119). Different
cellular oxidative status leads to different VOC metabolism. Thus, in vitro studies in
16
hypoxic or anoxic conditions would be a worthy approach in order to better reproduce
tumours environment.
Other factors can hamper the translation of in vitro to in vivo or ex vivo samples. For
instance, VOCs collected from culture cells may not be endogenous and rather be
originated from other sources (culture flasks, extraction procedures and sampling
conditions) (114, 120). In addition, different experimental design (from sample collection to
statistical analysis techniques), variations related to patients’ genetic and pathological
characteristics and the low number of in vitro studies compared with other matrices also
contribute for the discrepancies between the matrices. Furthermore, very little is known
about VOCs metabolism and how they are produced by cancer cells or what they are
consumed for. This is in fact considered the main challenge of VOCs analysis in cancer
biomarker discovery (97).
Despite the expectable low reproducibility of VOCs translation from in vitro to other
biological matrices, some studies have, however, shown common VOCs altered in cancer
cells and tissues, urine or exhaled breath (39, 107, 121, 122). This encourages furthering
investigation of potential VOC-biomarkers that can discriminate several cancer types as
well as other diseases, so that they can be employed as a diagnosis tool in clinics.
17
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2. METABOLOMICS RESEARCH IN BLADDER CANCER
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Biomarkers in bladder cancer: A metabolomic approach using
in vitro and ex vivo model systems
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Metabolomics has recently proved to be useful in the area of biomarker discovery for cancers in which early diagnostic and
prognostic biomarkers are urgently needed, as is the case of bladder cancer (BC). This article presents a comprehensive
review of the literature on the metabolomic studies on BC, highlighting metabolic pathways perturbed in this disease and the
altered metabolites as potential biomarkers for BC detection. Current disease model systems used in the study of BC metabo-
lome include in vitro-cultured cancer cells, ex vivo neoplastic bladder tissues and biological fluids, mainly urine but also blood
serum/plasma, from BC patients. The major advantages and drawbacks of each model system are discussed. Based on avail-
able data, it seems that BC metabolic signature is mainly characterized by alterations in metabolites related to energy meta-
bolic pathways, particularly glycolysis, amino acid and fatty acid metabolism, known to be crucial for cell proliferation, as well
as glutathione metabolism, known to be determinant in maintaining cellular redox balance. In addition, purine and pyrimidine
metabolism as well as carnitine species were found to be altered in BC. Finally, it is emphasized that, despite the progress
made in respect to novel biomarkers for BC diagnosis, there are still some challenges and limitations that should be
addressed in future metabolomic studies to ensure their translatability to clinical practice.
Bladder Cancer and the Need for Novel
Diagnosis Strategies
Bladder cancer (BC) is the second most common human
malignancy affecting the urinary system and one of the most
deadly cancers worldwide.1 Its incidence continues to rise
and mortality rates have remained unchanged over the past 3
decades, since successful treatments depend mainly on early
detection.2 Risk factors are associated with environmental,
dietary/lifestyle, especially smoking and genetic factors.3,4
BC is a heterogeneous and multifocal malignancy, being
divided in 3 main histological subtypes. Most BCs are transi-
tional cell carcinomas (TCC) (90%),5 also called urothelial
cell carcinomas since they develop from the cells of the blad-
der lining (urothelium). The other two types, squamous cell
carcinoma and adenocarcinomas, represent 10% of BC.5
Noteworthy, metabolomic studies on BC are, however, mostly
focused on urothelial bladder carcinoma. BC can be classiﬁed
as low-grade or high-grade, depending on the degree by
which cancer cells histologically differ from normal bladder
cells, being high-grade BC more aggressive and invasive than
low-grade.6 Furthermore, BC is also classiﬁed as superﬁcial
or nonmuscle invasive bladder cancer (NMIBC) and invasive
or muscle invasive bladder cancer (MIBC), based on the level
of invasion of the muscular bladder wall.6 Whereas NMIBC
is restricted to the lining of the bladder, MIBC spreads and
invades the muscle wall and other tissues/organs, and might
also cause metastatic spread.6,7 Remarkably, these two tumor
types display quite distinct molecular characteristics. Indeed,
NMIBCs are commonly near-diploid and have fewer genomic
rearrangements than MIBCs, which are often aneuploidy.
Moreover, up to 80% of NMIBC have activating point muta-
tions in FGFR3, whereas MIBC only displays this alteration
Key words: bladder cancer, biomarkers, metabolomics, metabolic
pathways, review, cell lines, tissue, urine, serum, bioﬂuids
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in about 20% of cases. Conversely, EGFR expression is upreg-
ulated in only 20% NMIBC, whereas this protein tyrosine
kinase is overexpressed in about 50% of MIBC. Nevertheless,
this categorization of BC failed to provided relevant prognos-
tic or predictive information for clinical application and
recent gene expression proﬁling studies found genetic signa-
tures that cross grade and stage groupings, with superior pre-
diction of clinical behavior.8
BC is mostly an asymptomatic disease at its inception,
with no speciﬁc symptoms, hindering its detection. The most
common symptom of BC is hematuria, occurring in 80%–
90% of the cases9—however, it may be caused by other uri-
nary diseases. Current standard diagnostic methods include
cystoscopy and urine cytology. The ﬁrst consists on the direct
observation of the bladder but it fails to visualize certain
regions and some cases of carcinoma in situ,10,11 apart from
being invasive and uncomfortable for patients. The latter
consists in microscopical examination of urine smears to
check for abnormal cells, blood and other markers.12 Urinary
cytology is noninvasive and highly speciﬁc, yet it lacks sensi-
tivity to detect low-grade tumors.13 Interestingly, there are
already some validated and approved molecular markers,
such as ImmunoCyt, UroVysion and bladder tumor antigen,
among others.14,15 Still, they lack speciﬁcity and its high costs
limit their use in clinical practice.
Early detection of BC is pivotal to improve overall survival
rate of patients. Since current diagnostic strategies are limited
in detecting early BC, there is a great need to search for
early, speciﬁc and cost-effective biomarkers, as well as nonin-
vasive detection tools, to improve BC diagnosis. Novel BC
biomarkers can also be valuable for prognostication, patient
stratiﬁcation and identiﬁcation of patients at high risk for
cancer recurrence and progression. As a result, better man-
agement of BC and successful treatment might be achieved.
Metabolomics, deﬁned as the comprehensive analysis of
all metabolites in a biological system, has gained importance
over the last years in the quest for promising, alternative
strategies for early cancer diagnosis. This “omic” approach
has been applied in cancer research since altered metabolism
is a widely recognized cancer hallmark.16 Cancer cells have
greater energetic needs than normal cells to fuel the high
DNA replication, protein synthesis rates and fast, constant
growth even in hostile environments. By reprograming their
metabolism, cancer cells are able to buildup sufﬁcient bio-
mass and to adapt, survive and proliferate under conditions
of stress.17,18 Consequently, metabolites excreted by cancer
cells will reﬂect alterations in the normal activity of metabolic
pathways, particularly glycolysis, amino acid and fatty acid
catabolism and its physiological status.19
Several studies have provided insight into how metabolo-
mics can be useful in cancer research, showing its great
potential not only toward the identiﬁcation of candidate can-
cer biomarkers but also in a better understanding of the
mechanisms underlying the pathogenesis of cancer. Metabo-
lomics studies have been applied to several cancer types
including those of the breast,20,21 ovary,22 prostate,23,24 kid-
ney,25,26 lung,27 brain28,29 and liver,30,31 with encouraging
results. Concerning BC, the applicability of a metabolomics
approach is limited compared with other cancers. Neverthe-
less, there are already some metabolomic studies on BC,
which will be highlighted in this review, as well as identiﬁed
potential biomarkers for BC early diagnosis.
Disease Model Systems for BC
Metabolomics Studies
Current disease model systems used in the study of BC
metabolome include in vitro cancer cell cultures, ex vivo neo-
plastic bladder tissues and human bioﬂuids.32 Each model
system has speciﬁc advantages and drawbacks, most notably
related to sample collection and handle and degree of
complexity.
In vitro culture systems, which comprise immortalized cell
lines and primary cell cultures, represent the least complex of
the various disease models and has a number of advantages
over tissue or bioﬂuid analysis, including simpler and con-
trollable experimental settings, reduction in animal testing
and providing a better insight into the metabolic changes.19
However, in vitro metabolomics has challenges related to
extrapolation to in vivo systems.33
Ex vivo BC tumor tissues are also important to consider
in these studies since it gives information on metabolites
altered within the solid tumor and in its microenvironment.34
Another advantage of using tissues is that the possibility of
collecting cancer and matched normal tissue samples from
the same patient strongly diminishes the inﬂuence of con-
founding factors. Nonetheless, tissue collection through surgi-
cal procedures is extremely invasive,34 needs special
equipment and expertise and requires inhibition of metabo-
lism at the moment of collection to avoid the induction of
“stress” metabolites.35 Tissues also have a limited availability
and high heterogeneity, making the samples preparation
more difﬁcult. Additionally, samples may be contaminated by
surrounding cells, thus special techniques are required to
heighten sample purity.32,34
Bioﬂuids have the advantage of being the easiest samples
to work with, being urine the most common sample analyzed
in BC metabolomics.34 Urine seems more likely to reﬂect
metabolic alterations occurring in BC since it directly con-
tacts with the tumor tissue and may contain tumor cells and
metabolites shed from the bladder tumor.36 The use of urine
as sample for metabolomic studies has a number of advan-
tages as compared with serum which include its noninvasive
nature, easier collection and handle, has relatively high ther-
modynamic stability, needs less sample preparation, has
higher amounts of metabolites, and it is a less complex
matrix, in terms of protein content. Nevertheless, urine com-
position is highly affected by several confounding factors,
such as age, environmental and dietary/lifestyle factors and
waste products, which consequently affects the metabolomic
proﬁle,15,37 and it is more prone to microbial contamination.
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Moreover, as a signiﬁcant number of patients will have the
primary tumor removed (e.g., cystectomy, nephroureterec-
tomy), if these patients relapse, urine will no longer be in
contact with the tumor and, accordingly, it is unlikely to be a
good model system in these patients. Blood serum/plasma is
also an important sample because its composition directly
reﬂects the metabolic processes occurring in the organism, it
is less affected by diurnal variations and confounding factors
compared with urine.34 However, its composition is more
complex than that of urine.34
Noteworthy, the comprehensive study of metabolome is
only possible through advanced and sophisticated methodolo-
gies. The analytical platforms most commonly used in metab-
olomics studies are proton magnetic resonance spectroscopy
(1H-NMR) and both liquid and gas chromatography (GC)
coupled to mass spectrometry (MS).35 Detailed description
on these techniques, as well as the statistical tools for metab-
olomics data analysis, is beyond the scope of the this article;
however, there are several studies on this matter.18,32,35,38,39
Metabolomic Studies in BC Model Systems and
Identification of Potential Biomarkers
Signiﬁcant progress in BC metabolomic research as well as a
better understanding of metabolic alterations related to the
development of this type of cancer has occurred. Studies on
this matter report alterations in the levels of some metabo-
lites in BC that could be potential candidate biomarkers for
clinical practice, which are summarized in Tables 1 and 2.
Cell line studies
There are just a few in vitro metabolomics studies in the lit-
erature, all of them attempting at proﬁling the metabolome
of immortalized BC cell lines (Table 1). The ﬁrst study
focused on the measurement of free and total glutathione
(GSH) levels in 5 human BC cell lines, namely, UCRU-BL-
13, -17 and -28, RT-4 and TCCSUP, and in 8 non-BC cell
lines (used as controls).40 It was observed that GSH levels
were signiﬁcantly higher in four of the ﬁve BC cell lines
(UCRU-BL-13, -17 and -28, RT-4), with the average GSH
concentration being 6-fold higher than in control cell lines.40
Increased GSH concentrations, as well as overexpression of
antioxidant enzymes,59,60 are crucial for the survival of cancer
cells under oxidative stress. Despite these results, GSH upreg-
ulation is a hallmark of cancer cells, meaning that it is not
speciﬁc for BC. In fact, GSH levels were similarly ranked in
other cancer types, namely, breast,61,62 kidney,63 liver,61,64
brain,65,66 lung,67 bone and prostate.61
Pasikanti et al. (2010) carried out a metabolomic
approach, using both GC-MS and GCxGC-TOF-MS techni-
ques. Metabolic ﬁngerprinting of immortalized nontumori-
genic human bladder cells (HUC-1) and their neoplastic
counterpart, HUC T-2 cells, revealed profound differences
between their metabolic phenotypes. Five and 20 metabolites
were identiﬁed by GC-MS and GCxGC-TOF-MS, respectively
(Table 1). Among them, glycine was the metabolite found at
higher levels, whereas 3-phosphoglyceric acid, a glycolytic
intermediate, was at lower levels in the HUC T-2 cells media
compared with that of HUC-1 cells.41 This is concordant
with the metabolic alterations observed in glycolysis since it
shows that glycine production through 3-phosphoglyceric
acid is upregulated. Furthermore, as glycine is an essential
source of one-carbon units for nucleotide synthesis, it also
emphasizes that this metabolic pathway is upregulated as
well.
Dettmer et al. (2013) performed a study involving numer-
ous immortalized human cancer cell lines, including BC cell
lines J82 (high-grade) and RT4 (low-grade), to identify differ-
ences in their metabolic proﬁles. In total, 700 metabolite fea-
tures were found, but only 42 were discriminative (Table 1).
All cancer cells presented higher production of lactate, higher
assimilation of amino acids and higher levels of extracellular
arginine and nicotinamide.42 This evidences the increase
in biosynthetic activity and in bioenergetics demands
of cancer cells.
To further investigate whether the metabolomic signature
is altered with progression of cancer, a study was recently
carried out to look at the glycolytic proﬁle of RT4 and
TCCSUP cell lines, low- and high-grade BC, respectively.43
Samples collected from the extracellular medium were ana-
lyzed by 1H-NMR. Glucose consumption was found to be
similar in both cell lines, though it was slightly higher in the
highly invasive cancer cells. TCCSUP cells also presented
increased pyruvate consumption, higher levels of alanine and
lactate than in the RT4 cells.43 This suggests that alterations
in the metabolism of pyruvate and in lactate production are
somewhat related to BC development and progression, from
lower to higher grades. In fact, the enhanced glucose uptake,
required for ATP production, and the insufﬁcient oxygen
supply, caused by the rapid proliferation and deﬁcient blood
deliver which generates anaerobic conditions,26 favors the
conversion of pyruvate to lactate. In addition, the conversion
of pyruvate to either lactate or alanine is coupled with the
conversion of NADH to NAD1, an essential metabolite for
the maintenance of the glycolytic ﬂux in cancer cells.68
Ex vivo tissue studies
Strengthening the importance of GSH in the protection
against tumor microenvironment-related aggression, a study
conducted by Pendyala et al. (1997) also showed higher levels
of GSH in BC tissue compared with those of healthy
controls.40
Putluri et al. (2011) performed a study aiming at the iden-
tiﬁcation of potential candidate biomarkers through BC
metabolomic signatures and unravel bioprocesses associated
to BC carcinogenesis. The metabolic proﬁles of BC and
benign-looking adjacent tissues, as well as healthy controls,
were determined by LC-MS.44 Fifty metabolites exhibited sig-
niﬁcant differences in BC tissues when compared with the
benign ones. Among the perturbed metabolites, elevated lev-
els of amino acids, namely, serine, asparagine, valine,
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phenylalanine and histidine were found in BC tissues. More-
over, levels of S-adenosyl methionine (SAM) were also higher
in BC tissues as well as aniline, a xenobiotic involved in blad-
der carcinogenesis,69 whereas levels of taurine, and palmitic,
lauric and oleic acids were decreased in BC compared with
adjacent benign tissues.44 The combination of these metabo-
lites was able to distinguish both normal and benign tissues
from BC tissues. Focusing on the same issue, Tripathi et al.
(2013) performed a 1H-HRMAS-NMR-based metabolomics
analysis of benign and BC tissues, in which it was observed
that BC tissues exhibited more metabolic abnormalities than
benign ones, resulting in a clear differentiation between
benign and BC patients. Nevertheless, this method was not
able to distinguish various BC pathological stages (Ta/T1
versusT2), thus suggesting that metabolic features of dif-
ferent BC stages are difﬁcult to separate. Twenty-two metab-
olites were found to be altered in BC tissues and cross-
validation via targeted GC-MS analysis of the same tissue
samples demonstrated the potential of those biomarkers for
clinical diagnosis of BC. Potential metabolites included: tri-
glycerides, which were decreased in BC tissues, and inter-
mediates of glycolysis and TCA cycle, amino acids, taurine,
GSH and choline-containing metabolites, which were elevated
in BC tissues compared with benign tissues.45
Both studies substantiate the enhancement in amino acid
metabolism, a consistent hallmark of cancer development,
and in methylation, due to increased SAM levels,44 consistent
with increased DNA and protein synthesis. Another hallmark
of cancer is the aberrant formation of cell membranes,
pointed out by the altered levels of choline-containing com-
pounds.45 However, levels of taurine were contradictory
between the studies, either found down-44 or upregulated.45
Human biofluids studies
Blood plasma/serum studies. Two very promising 1H-
NMR-based metabolomics studies on serum were performed
aiming at the distinction between BC patients and healthy
controls, along with tumor stages. The one performed by
Cao et al. (2012) examined the serum proﬁle of patients with
either high- or low-grade BC and included patients with uri-
nary calculi (presenting with hematuria, as BC patients do)
in the control group. Statistical analysis demonstrated that
BC patients could be distinctly separated from both healthy
controls and patients with calculi. Notably, metabolic proﬁles
allowed for the distinction between low- and high-grade BC
as well. It was observed that the serum levels of isoleucine/
leucine, tyrosine, phenylalanine, choline, lactate, glycine and
citrate were lower in BC patients compared with healthy sub-
jects, whereas the levels of lipids and glucose were higher in
BC patients. Compared with calculi patients, serum levels of
metabolites in BC patients presented with the same trend of
changes. Comparisons of the metabolite levels between low-
grade and high-grade BC patients showed that levels of tyro-
sine, phenylalanine, lactate and glycine were higher in low-
grade, whereas the levels of glucose were lower than those of
high-grade BC.47
The second study was performed using serum samples
from low- and high-grade BC patients, and healthy con-
trols.48 The statistical model was able to differentiate between
BC patients and healthy individuals, as well as low- versus
high-grade BC patients with high sensitivity and speciﬁcity.
Six metabolites—dimethylamine (DMA), malonate, lactate,
glutamine, histidine and valine—were found signiﬁcantly dif-
ferent between the healthy and cancer groups (Table 2).
Among those metabolites, glutamine was found at increased
levels in low-grade BC, whereas DMA and malonate were
found increased in high-grade BC. Of importance, in this
study a new group of 106 suspected BC patients was also
analyzed for external validation through a double-blind study,
which conﬁrmed the helpfulness of the metabolomic platform
for the early diagnosis of BC.48
Serum-based metabolomics showed alterations in the
energetic metabolism, particularly increased fatty acid synthe-
sis and anaerobic glycolysis, as an alternative energy supply,
and glycerophospholipids metabolism (higher levels of
DMA), for cell membrane formation. These studies also evi-
denced the possibility to evaluate whether it is low- or high-
grade BC. Lactate has been already associated with cancer
progression.43 Tyrosine, phenylalanine and glycine seem to
play a major role in cancer pathogenesis,70,71 glutamine
metabolism provides additional energy for the uncontrolled
proliferation72 and malonate is assumed to inhibit the respi-
ratory chain Complex II (succinate dehydrogenase) to help
cancer cells against ROS production.73
Urine studies. A 1H-NMR-based urine metabolomics study
was carried out to investigate metabolic pathways perturbed
in NMIBC.50 Urines from BC patients, benign controls and
healthy controls were analyzed (Table 2). A signiﬁcant
increase in the levels of taurine in BC samples compared
with controls was observed, whereas levels of citrate, phenyl-
alanine and hippuric acid were found to be decreased in BC.
However, in this study, the stages of BC could not be deter-
mined based only on the indices of the altered metabolites
and the sensitivity and speciﬁcity of this method were not
validated. Based on this study, Gamagedara et al. (2012)
developed a LC-MS/MS method to quantify taurine, phenyl-
alanine and hippuric acid in urine, but including normaliza-
tion to creatinine levels, being observed the same trend of
changes. Taurine is a semiessential amino acid important as
an osmolyte, antioxidant, free-radical scavenger, that protects
cells against oxidative damage.74,75 It also inactivates hypo-
chlorous acid, a strong cytotoxic oxidant, by forming a stable
complex, taurine-chloramine, which down-regulates immune
responses leading to tumor development.74 Taurine might be
considered a good candidate for BC diagnosis since its
increase in BC urine is concordant with its upregulation in
BC tissues.45 Nevertheless, higher concentrations of taurine
have been reported in other cancers as well.76–78
M
in
i
R
ev
ie
w
264 Biomarkers in bladder cancer
Int. J. Cancer: 139, 256–268 (2016) VC 2016 UICC
30
Pasikanti et al. (2010) were also able to distinguish BC
patients from healthy controls using another platform, GC-
TOF-MS, with 100% sensitivity. Furthermore, and despite the
need for a larger cohort to validate these results, the authors
established a robust proof-of-principle for GC-TOF-MS-
based metabolomics in staging and grading bladder
tumours.51 Among the 32 metabolites selected, 15 of them
were signiﬁcantly altered (Table 2), including valine, citrate,
glycerol, melibiose, ribitol, gluconic acid, uridine, among
others. A more recent study by the same group55 is resumed
in Table 2, and, interestingly, it suggested the potential role
of kynurenine in the development of BC due to alterations in
the tryptophan metabolism. Upregulation of tryptophan met-
abolic pathway leads to higher concentrations of anthranilic
acid and N-acetyl-anthranilic acid,55 kynurenine,42,44 trypto-
phan44,54 and N-acetyltryptophan.54 These metabolites have
been indicated as BC carcinogens, as their structure is similar
to environmental ones.79 Excessive tryptophan metabolites
seem to play a role in suppressing antitumor immune
responses, thus promoting cancer cells survival, through acti-
vation of aryl hydrocarbon receptor, which is involved in
carcinogenesis.80,81
Two other studies carried out a LC-MS-based metabolo-
mic analysis of urine2,56 to build a screening model for BC
diagnosis. Noteworthy, one of the studies included hematuria
controls to exclude possible confounding effects of benign
hematuria.56 Various discriminative metabolites were identi-
ﬁed in both studies (Table 2), particularly several altered car-
nitine species. Carnitine was found increased in BC urines, as
well as isovalerylcarnitine, octenoylcarnitine and acetylcarni-
tine, consistent with the results from another BC urine
study54 and a BC tissue study.44 Decreased levels of decanoyl-
carnitine, glutarylcarnitine and 2,6-dimethylhptanoyl carni-
tine were found in the cancer group. Additionally, the levels
of carnitines were higher in MIBC than NMIBC,56 which
suggests that they may be correlated with BC aggressiveness,
hence can be useful to distinguish grades of cancer. Further-
more, urinary levels of acetyl-CoA were also found elevated
in BC patients.56 Concerning carnitine, it is essential in the
fatty acid b-oxidation, facilitating the entry of fatty acid into
the mitochondria and acetyl-CoA is the end product of that
oxidation. Therefore, excess acetyl-CoA and altered levels of
carnitine species evidence that fatty acid b-oxidation is dysre-
gulated in BC, consistent with other urine studies on this
cancer.54,57,58 Increased glycolysis and impaired TCA cycle
might also lead to acetyl-CoA accumulation and its shift
toward carnitine shuttle and fatty acid b-oxidation. More-
over, decreased citrate levels found in BC42,47,50,51,55 reﬂect
the increased conversion of citrate into fatty acids necessary
for b-oxidation to support the rapid proliferation of cancer
cells.
As expected, perturbations in purine and pyrimidine met-
abolic pathways were observed, due to enhanced cancer cells
cycle activity. Pyrimidine metabolism was found upregulated
due to elevated levels of uridine and pseudouridine in
BC,51,55 which are metabolites involved in RNA synthesis
and reﬂect a greater energetic state of the tumor cells, and
decreased levels of ureidosuccinic acid,58 which may reﬂect
its higher consumption for pyrimidine synthesis. Likewise,
purine metabolism was found elevated with higher levels of
hypoxanthine and decreased levels of uric acid,54 adenosine
and inosinic acid. In the normal breakdown of purine nucle-
otides, hypoxanthine is formed and converted to uric acid. In
cancer cells, this pathway is dysregulated as purine synthesis
is favored, therefore uric acid is diminished and hypoxan-
thine is accumulated for the de novo synthesis of purines.
This bioprocess also explains the decreased levels of adeno-
sine and inosinic acid in BC patients.
Conclusions and Future Perspectives
Overall, BC displays perturbations in several metabolic path-
ways, which involve essential biochemical reactions that gen-
erate energy, namely, glycolysis, TCA cycle, fatty acid b-
oxidation, carnitine shuttle and amino acids metabolism, par-
ticularly the upregulation of tryptophan metabolic path-
way.34,42,44,48,54–56 This would be expected because cancer
cells, in general, require more energy to grow and proliferate
faster than normal cells. In turn, elevation of GSH levels was
also noticed in this urological cancer,40,45 consistent with its
synthesis induction as a response to the higher oxidative
stress in cancer cells. Concerning the alterations in glycero-
phospholipids metabolism, levels of choline and choline-
containing compounds were found either elevated in BC tis-
sues45 or decreased in serum47 and urine samples2 from BC
patients, which suggests either accumulation or excess con-
sumption of these metabolites for the rapid cell membranes
formation. Upregulation of purine and pyrimidine metabo-
lism were also observed in urine,51,54,55,57,58 tissues44,45 and
cell lines,41 consistent with the higher rate of nucleic acid
synthesis. The aforesaid studies indicate some promising
metabolites that may be considered as good candidates for
early detection of BC and disclose the main metabolic path-
ways dysregulated in BC, which are outlined in Figure 1.
Interestingly, some studies were able to distinguish
between early and advanced stages of BC through the levels
of certain metabolites.43,47,48,54,56,58 The tendency of changes
in some metabolites, including glucose, lactate,43,47 tyro-
sine,47,54 phenylalanine, glycine,47 DMA, malonate, gluta-
mine,48 carnitine species,54,56 hypoxanthine and uric acid,54
was consistent with BC aggressiveness and stage of metasta-
sis. These results suggest that different stages/grades of BC
might generate distinct metabolic proﬁles, which might be
due to the fact that cancer cells in advanced grades/stages
require more energy for survival and continuous growing.
Moreover, the replacement of the conventional two-pathway
model of BC pathogenesis by complex molecular signatures
that have been proposed based on large-scale genome-wide
proﬁling studies (e.g., TCGA consortium, COSMIC) will
require a shift in data analysis of the metabolomics proﬁling
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of BC. Indeed, future metabolomics studies will have to nec-
essarily entail these new molecular signatures.8
Despite the progress of metabolomics in cancer research,
there are still some challenges and limitations. For instance,
the inadequate number of patients recruited in each study
and small validation cohorts difﬁcult the translation of
metabolites to clinical practice. Additionally, only a few stud-
ies carried out a quantitative method to validate the key
metabolites, because it can be challenging and time-
consuming due to lack of standardized quantiﬁcation meth-
ods.34 Notably, there is some inconsistency and relatively lit-
tle overlap between biomarkers identiﬁed among the studies,
even when the same specimens were analyzed. This may be
due to a series of factors, such as the work environmental
conditions, different handling and storage of samples,35
which may alter the already dynamic and sensitive metabolic
proﬁle, and the use of different analytical techniques that
cover different metabolites. Another important challenge of
metabolomic studies is that they are particularly affected by
various confounding factors related to the patients, such as
the genetic background, age, gender, lifestyle/diet, medication,
surgical intervention and other pathological conditions.15,34
This is particularly important in the case of urinary metabo-
lomics since urine composition is highly affected by those
factors and it may lead to false results.
In future metabolomic investigations, it is important to
bear in mind that a good BC biomarker should be able not
only to detect BC, but also to distinguish low- from high-
grade BC, for a better diagnosis. Further developments
and application of metabolomics will depend on various fac-
tors, such as the creation of a database containing the
metabolites characteristic of BC, and their biochemical iden-
tities and interactions. It would be also interesting to inte-
grate the metabolomic results with those obtained from
other “omics” studies in order to cover all features of a cer-
tain cancer. Likewise, continuous development of high-
throughput analytical platforms coupled with the improve-
ment of bioinformatics tools will help overcome some limi-
tations. Furthermore, standardization of the experimental
design and analytical methods for biomarkers discovery is
required, so that results become more comparable and vali-
dation of potential biomarkers can be achieved. Elimination
of systematic effects of confounding variables on metabolite
measurements needs further consideration as well, so that
differences detected by multivariate analysis correspond to
genuine changes in the levels of metabolites. Once these
challenges and limitations are overcome, speciﬁc metabolites
with potential clinical usefulness may be identiﬁed to aid in
BC diagnosis, as well as in prognostication and long-term
surveillance.
Figure 1. Schematic illustration of significant dysregulated metabolic pathways in BC, highlighting potential metabolite biomarkers. Metabo-
lites downregulated are shown in red and those upregulated are shown in green. AMP, adenosine monophosphate; ATP, adenosine triphos-
phate; DMA, dimethylamine; GSH, glutathione (reduced form); GSSG, glutathione (oxidized form); PPP, pentose phosphate pathway; TCA,
tricarboxylic acid (cycle); UMP, uridine monophosphate; UTP, uridine triphosphate. [Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
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3. AIMS OF THE EXPERIMENTAL WORK
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Concerning BC, there have been great attempts to improve diagnostic strategies and
several potential markers have been described over the years or are under investigation,
and some of them have already been validated and approved to be used in clinical
practice (58, 123-125). Nevertheless, most still fail the early detection of this malignancy,
presenting no advantages over classical diagnosis methods (126), and their high cost limit
their application in clinical practice (123). Therefore, the need to find more accurate,
disease-specific and easily detectable and economical biomarkers is urgent.
BC metabolomics studies, as described in the previous chapter, have shown
promising results and good potential biomarkers, but there is still a lot to be done.  With
the hope of contributing to the search of BC biomarkers and to the better understanding of
BC metabolism, the present work focused on performing an untargeted metabolomic
study, using in vitro BC cell lines. Despite its aforementioned disadvantages, the in vitro
model system was chosen due to the lower complexity in processing the samples and in
controlling the experimental settings, compared with other matrices, and because it
provides a first insight on the metabolic alterations that may occur in the organism in the
presence of BC.
The overarching goals of the present work are as follow:
a) Application of HS-SPME/GC-MS based metabolomics for the metabolic profiling
of 3 different tumorigenic bladder cell lines and of a non-tumorigenic cell line to
search for significant differences among them.
b) Evaluation of two different pHs (pH 2 and 7) in order to infer which pH is optimum
for VOCs extraction that can be applied in future in vitro metabolomic studies.
c) Screening, statistical analysis and possible identification of VOCs that contribute
to the separation of the cell lines.
d) Evaluation of the potential of the metabolic signature found for discrimination of
different types and grades of BC.
VOCs were analysed due to their great potential as biomarkers and the relatively
easy translatability to other biological matrices (such as urine or exhaled breath). In
addition, analysis of VOCs using HS-SPME/GC-MS requires simpler and faster sample
preparation, which can be seen as an advantage in a clinical environment. Furthermore,
to our knowledge, there is no BC metabolomic study that performed the VOCs profiling in
in vitro cell lines, making this work pivotal in that matter.
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4. EXPERIMENTAL WORK – MATERIAL AND METHODS
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4.1. Chemicals
Minimum Essential Medium Eagle (MEM) and Ham’s F-12 K nutrient mixture
powder, both supplemented with L-glutamine, were purchased from Sigma-Aldrich (St.
Louis, MO, USA). Penicillin, streptomycin and trypsin were purchased from Invitrogen
(Karlsruhe, Germany); fetal bovine serum (FBS) was purchased from PAA laboratories
GmbH (Colbe, Germany); DMSO (99.0%) and hydrochloric acid (HCl) were obtained from
Merck (Darmstadt, Germany). Sodium chloride (NaCl, ≥99.5%), sodium hydroxide (NaOH,
≥97%), Folin-Ciocalteu’s phenol reagent, bovine serum albumin (BSA) and 4-
fluorobenzaldehyde (98%) were purchased from Sigma-Aldrich (St. Louis, MO, USA), and
methanol (99.9%) from VWR (Leuven, Belgium).
All chemicals were of analytical grade and were dissolved in deionized water unless
otherwise indicated.
4.2. Cell lines and culture conditions
The BC cell lines, namely J82, Scaber and 5637 were kindly provided by Instituto
Português de Oncologia do Porto (IPO). The non-tumorigenic SV-HUC 1 was obtained
from American Type Culture Collection (ATCC; Manassas, VA, USA). General
characteristics of all cell lines are summarized in Table 1. All cancer cell lines were
cultured in plastic T75 culture flasks containing 15 mL of MEM whereas SV-HUC-1 was
cultured in plastic T75 culture flasks containing 15 mL of Ham’s F-12 K medium. Both
medium were prepared as indicated by the manufacturer and supplemented with 10%
FBS and 50 units.mL-1 penicillin/50 μg.mL-1 streptomycin. To minimize possible effects of
the used medium on metabolic footprints, the culture conditions were kept constant
throughout the entire study. All cell lines were incubated at 37ºC and 5% CO2.
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Table 1. Characteristics of BC and normal cell lines used in this study.
SV-HUC-1 5637 J82 Scaber
Organism Homo sapiens Homo sapiens Homo sapiens Homo sapiens
Gender/Age
(years) male/11 male/68 male/58 male/58
Tissue ureter,uroepithelium urinary bladder urinary bladder urinary bladder
Cell type epithelial SV40immortalized primary tumour primary tumour primary tumour
Morphology epithelial epithelial epithelial epithelial
Culture
properties adherent adherent adherent adherent
Tumorigenic no yes yes yes
Disease - TCC TCC SCC
Grade - II III/IV III/IV
Stage - NA pT3 pT4
NA, not available; SCC; squamous cell carcinoma; TCC, transitional cell carcinoma
4.3. Collection of VOCs from extracellular medium
The experiments were carried out during 5 passages (passages 4 to 8 in the case of
cancer cell lines and passages 6 to 10 in the case of SV-HUC-1) and in triplicate for each
passage, resulting in a total number of 60 experiments. After cells’ growth to maximum
confluence was achieved, medium from each T75 culture flask was discarded and 15 mL
of fresh medium was added and incubated at 37 ºC for 48 h. Afterwards, the extracellular
medium was transferred to falcons on ice and centrifuged for 4 minutes at 2000 xg at 4
ºC. The supernatant was divided into 2 aliquots of 7 mL, for further samples analysis at
two different pHs, and stored at -80 ºC until analysis. The remaining pellets were used for
posterior protein quantification (described in 4.4).
T75 culture flasks containing only medium (controls) were treated in an identical
manner. Controls medium was submitted to the same collection and storage conditions.
4.4. Protein quantification
Pellets were used to quantify protein content so that cellular density in each flask
could be verified. It was applied the Lowry method (127), which is based in two reactions:
(1) production of Cu+ due to the reaction between peptide bonds of proteins with cupper
under alkaline conditions; (2) reaction of Cu+ with the Folin-Ciocalteau reagent that leads
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to its reduction, and, consequently, it results in a strong blue colour solution that absorbs
between 650 and 750 nm (128). The method’s sensitivity is around 0.1 mg of protein.mL-1.
Firstly, a calibration curve was obtained using different concentrations of a BSA
stock solution 2000 μg.mL-1, prepared in NaOH 1M. Secondly, different dilutions of the
pellets in NaOH 1M were tested, so that the dilution with the most reproducible results and
within the calibration curve was chosen. Afterwards, 50 μL of BSA, 100 μL of Solution A
(Na2CO3 2%, CuSO45H2O 1%, KNaC4H4O6 2%) and each pellet sample were added in
each well of a 96-well plate. The plate was then covered for 10 min, after which 100 μL of
Solution B (Folin-Ciocalteau reagent 1M) was added and the plate covered again for 20
min. Absorbances were measured at 750 nm in a Power Wave X microplate reader (Bio-
Tek Instruments, Inc.; Winooski, VT, USA).
4.5. Sample preparation for HS-SPME/GC-MS analysis
4.5.1. Metabolic profiling of VOCs
Stored samples were thawed slowly in ice to minimize the loss of volatile
compounds. Two mL of each sample were collected to a 10 mL glass vial, capped with a
polytetrafluoroethylene (PTFE) septum and a screw cap, containing 0.59 g NaCl and 10
μL of internal standard (IS) 4-flurobenzaldehyde (Millipore, Bedford, MA, USA) with final
concentration of 10 μg.mL-1. As aforementioned, medium of each cell line and controls
were analyzed at two different pHs (pH 2 and 7) in order to evaluate which pH is optimum
for VOCs extraction. For pH 7 samples, there was no need to adjust the pH. After
measuring all samples pH, the median pH was 7.252 ± 0.088. In the case of pH 2
samples, 70 - 75 μL of a 5 M HCl solution was added to adjust the pH, whose median was
2.076 ± 0.045.
4.5.2. QC samples
QCs were prepared as a pool of all samples in the study, where 200 μL of each
sample was gathered in one single sample. Subsequently, the sample was divided into
aliquots to avoid the constant freezing and thawing.
4.6. HS-SPME/GC-MS analysis: equipment and conditions
A general illustration of HS-SPME method coupled with GC is represented in figure
2. The HS-SPME measures were performed using a Combi-PAL autosampler (Varian Pal
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Autosampler, Switzerland) and the Cycle Composer software (CTC Analytics System
Software, Switzerland). Headspace (HS) volatiles were extracted by exposing a 65 μm
film thickness polydimethylsiloxane/divinylbenzene (PDMS/DVB) fiber (Supelco Inc.,
Bellefonte, PA), previously conditioned at 250 °C for 30 minutes. The HS-SPME method
was developed and optimized previously by our group (118). The HS was generated after
5 min. of incubation and 20 min. of extraction, at 45 °C.
The chromatographic analysis of the VOCs extracted from the extracellular medium
were performed on a SCIONTM SQ (single quadrupole) 436-GC-MS system (Bruker
Daltonics, Fremont, CA) equipped with a SCION SQ ion trap mass detector and a Bruker
Daltonics MS workstation software (version 8.2). A capillary column VF-5 ms (30 m x 0.25
mm x 0.25 μm) from Varian was used for the chromatographic separation. Helium C-60
(Gasin, Portugal) was used as the carrier gas at a constant flow rate of 1.0 mL/min. The
injection was in splitless mode and the injector temperature was 230 °C (held for 20 min.).
As for the oven temperature, it was held for 1 min at 40 °C, followed by an increase at a
rate of 5 °C/min until reaching 250 °C (held for 5 min) and finally an increase of 5 °C/min
to 300 °C (held for 1 min). The MS detector was operated in EI mode. Data acquisition
was performed in full scan mode with a mass range between 40-350 m/z at a scan rate of
6 scan/s.
QCs were analysed under the same conditions, on every 15 samples.
Figure 2. Schematic representation of a typical HS-SPME performed in the present work.
Illustration was based on figure 3 from Pragst et. al (129).
4.7. GC-MS data pre-processing
VOCs identification in HS-SPME/GC-SQ/MS chromatograms of extracellular
medium was performed based on the comparison of their retention times (RTs), Kovats
retention index (RI) and mass spectra from the NIST mass spectral library (2014). The RI
Extracellular
medium + IS +
NaCl
Incubation and headspace
generation
Sample injection
through GC injector
Sample extraction from the
headspace, at 45 °C during
20 min.
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of the analytes was calculated according to the retention times obtained for a solution of
n-alkanes (C8-C20) series, which was analysed under the same chromatographic
conditions as the set of samples. Only a reverse match of 700 or above was considered in
the compound identification whereas compounds for which no satisfactory match was
found were listed as “Unknown i” (i=1,2,3…) according to their crescent RTs. The HMDB
(130) and KEGG (131) databases were also consulted to aid in the identification of
compounds and interpretation of possible disturbed metabolic pathways.
All raw data files obtained from HS-SPME/GC-SQ/MS were exported as CDF files
and pre-processed in order to convert instrumental data sets into a manageable format for
data analysis and remove any bias such as background, noise and RT fluctuations over a
set of samples. Data pre-processing was performed using the software MZmine 2.21
(132) and consisted in baseline correction, peak detection, chromatogram deconvolution,
alignment and normalization. Baseline correction was applied to remove random noise
and baseline shift in the raw data. Peak detection enabled the identification of all
individual peaks caused by true ions avoiding detection of false positives. Chromatogram
deconvolution was used to separate two or more co-eluting peaks in GC chromatogram
using MS spectra. Alignment consisted in matching equivalent peaks across multiple
samples. The parameters used in these steps were set as follow: RT range 2.8-34.0 min;
m/z range 50-250; MS data noise level 1.0104; m/z tolerance 0.5 or 5 ppm;
chromatogram baseline level 1.0103; peak duration range 0.02-0.30 min. After pre-
processing steps, artefact peaks such as GC contaminants (e.g., cyclosiloxanes,
siloxanes and phthalates) were removed from data matrix, as well as all peaks with
relative standard deviation (RSD)  30 % across all QCs, as an indicator of poor
reproducibility and repeatability of the analysis. Data was subsequently normalized by
total area (TA) by dividing each peak area in the chromatogram by the total peak areas of
the respective chromatogram. TA normalization is useful for correcting minor variations
that derive from sample preparation and analysis (37). The resulting m/z-RT pairs, sample
names and normalized peak areas were subjected to statistical analysis.
4.8. Statistical analysis
The final matrix was imported to SIMCA-P 13.0.3 (Umetrics, Umea, Sweden) and
scaled to pareto (Par), which applies the square root of the standard deviation as a
scaling factor to reduce the relative importance of small variables that might be from
irrelevant peaks (133). PCA was first applied to detect trends and outliers, followed by
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PLS-DA, used to discriminate between classes and identify the metabolic signature
associated with a specific sample class. Model robustness was initially evaluated in terms
of R2X (variance explained by the X matrix, i.e. GC-MS data), R2Y (variance explained by
the Y matrix, i.e., sample class) and Q2 (goodness of prediction or prediction power), a set
of parameters obtained by 7-fold cross validation in SIMCA-P 13.0.3 software. The most
discriminative variables (m/z-RT pairs) responsible for group separation were assessed
through inspection of PLS-DA loadings scatter plots and the corresponding variable
importance to the projection (VIP) of each variable. Only variables with VIP>1 were
considered as important for group discrimination. Monte Carlo cross validation (MCCV) (7
blocks, 500 runs) was also carried out to evaluate the robustness of the PLS-DA models
using a software developed in the University of Aveiro (134). The prediction power (Q2)
and confusion matrices of each model were computed for original and permuted
(randomly splitting sample group) models. PLS-DA models were considered robust when
minimal overlapping of the distribution of original and permuted Q2 was obtained (135,
136). Classification rates, specificity (spec.) and sensitivity (sens.) were recovered for
each PLS-DA model through a receiver operating characteristic (ROC) map.
The statistical significance of relevant compounds identified in the loadings scatter
plots was computed using GraphPad Prism version 6 (GraphPad Software, San Diego,
CA, USA). Firstly, Shapiro-Wilk normality test was applied to determine if data assumed a
Gaussian distribution. For normally distributed data, an unpaired Student’s t-test with
Welch correction was applied, whereas for non-normally distributed data, an unpaired
Mann-Whitney test was used. For each model, the discriminative compounds were
considered statistically significant when p-value < 0.05 (confidence level 95%). Bonferroni
correction (137) was used to adjust p-values for multiple comparisons by setting the
significance cut-off to /n, where = 0.05 and n represents the number of compounds
simultaneously tested in univariate statistical analysis. Furthermore, for each significant
compound, the effect size (calculated as described in Berben et. al (138)), percentage of
variation and uncertainty were determined. Finally, PCA and PLS-DA were performed
using the set of statistically significant compounds in order to further confirm the
robustness of the metabolic signature found for each cancer cell type compared with the
normal cell line. In order to confirm the robustness of the PLS-DA including only the
discriminative metabolites, MCCV was also performed. Moreover, an example of a
correlation network analysis (Gephi) of VOCs from both pHs selected as significant in
discriminating the cancer cell line J82 (HG BC) from the normal cell line SV-HUC-1, based
on Spearman’s correlation coefficients (r 0.8 and p < 0.01) was carried out in order to
better understand how compounds would correlate.
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5. RESULTS
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5.1. Data pre-processing and chemometric analysis
As aforementioned, in any in vitro metabolomic study it is necessary to take into
account the cellular density, because it will affect the metabolite concentration of the
samples. Although maximum cell confluence was assured before sample collection,
protein quantification was measured to confirm if cells density was identical in all culture
flaks. Indeed, data obtained for protein quantification was identical among all bladder cell
lines (Supplementary Table S1, Appendix), showing that there was little difference in cell
density per culture flask. Hence, data was not normalized for protein concentration but
rather by chromatograms TA, as described previously.
Two different pHs were analysed to evaluate which one would yield better results
and, therefore, be most appropriate in future in vitro metabolomic studies for VOCs
extraction. In general, a variety of chemical compounds was detected in both pH 2 and pH
7, such as alcohols, aldehydes, ketones, alkanes, esters, carboxylic acids and
monoterpenoids.
5.1.1. GC-MS analysis of the samples at pH 7
The GC-MS analysis of the extracellular medium at pH 7 consistently resulted in a
total of 191 peaks. Representative full scan chromatograms of each cell line are
presented with some of the most abundant compounds, as well as their respective
controls medium (figure 3).
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Figure 3. A. Representative full scan chromatograms obtained from the analysis of the
extracellular medium of (a) SV-HUC-1, (b) 5637, (c) J82 and (d) Scaber, at pH 7. B. Representative
full scan chromatograms obtained from the analysis of the controls medium of (a) SV-HUC-1 and
(b) 5637, J82 and Scaber, at pH 7. Legend: 1. 2-4-dimethylhept-1-ene; 2. cyclohexanol; 3. 4-
fluorobenzaldehyde (IS); 4. 2-ethyl-1-hexanol; 5. 4-methylbenzaldehyde; (6) 2-phenylpropan-2-ol;
7. 1-phenoxypropan-2-ol; 8. unknown; 9. 2-ethyl-3-hydroxyhexyl 2-methylpropanoate; 10. 2-
pentadecanone. Note: the compounds are characterized by their IUPAC names.
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With the aim of confirming that analytical variation was minimal and the method was
reproducible, a pool of samples was analysed (QCs). Indeed, all QCs were closely
clustered and centred in the PCA-X score scatter plot (figure 4), demonstrating the
reproducibility of the method. Since the analytical variation was not significant, it is
possible to infer that variations in the metabolites concentrations were mainly due to
differences between the bladder cell lines.
In figure 4 it is also possible to observe a clear separation on the first principal
component (PC1) between the culture medium of the cell lines and the controls.
Figure 4. PCA-X score scatter plot obtained for the HS-SPME/GC-MS chromatograms of all
samples, at pH 7, namely the medium of the controls (n=60, ●), QCs (n=8, ●) and the extracellular
medium of all cell lines (n=60, ●). The ellipses indicate the 95% confidence limit of the model.
PCA-X and PLS-DA scores scatter plots were performed considering only the
extracellular medium of the bladder cell lines, in order to study which compounds were
responsible for the separation. The multivariate statistical models showed a clear
separation between the extracellular medium of cancer cell lines and the one from the
normal cell line, on the first principal component (PC1) (figures 5a to 5f). Values for R2X,
R2Y and Q2 for each PLS-DA model are also presented in the figures. Of note, one
sample from SV-HUC-1 group was excluded from the PLS-DA model and from the
following statistical analysis since it was considered an outlier, a decision based on the
facts that the intensity of its chromatographic peaks was divergent from the rest of the
samples and, when included in the PLS-DA models, it significantly diminished the Q2
values. Moreover, in figures 6a and 6b, it is also illustrated an example of a PLS-DA
model (Scaber vs SV-HUC-1) and its respective loading scatter plot that enabled the
identification of the metabolites responsible for group separation (VIP>1), and their
changes were verified by visual interpretation of boxplots performed on Graphpad and by
t[2
]
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determining the % of variation and effect size values. This method was performed for all
cell lines comparisons. It is also represented the Q2 distribution and ROC plot of true and
permuted classes in figures 6c and 6d, respectively, obtained by MCCV (Table 2) for the
PLS-DA model exemplified in figure 6a.
Figure 5. (a), (c) and (e) PCA-X and (b), (d) and (f) PLS-DA scores scatter plots obtained for the
HS-SPME/GC-MS chromatograms of the normal cell line (SV-HUC-1, n=14, ●) and the cancer cell
lines 5637 (n=15, ●), J82 (n=15, ●) and Scaber (n=15, ●) extracellular medium (pH 7), respectively.
The ellipses indicate the 95% confidence limit of the model.
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Figure 6. Example of the method used for the identification of the most significant metabolites
represented by (a) PLS-DA score scatter plot obtained for the HS-SPME/GC-MS chromatograms
of the normal cell line (SV-HUC-1, n=14, ●) and Scaber (n=15, ●) extracellular medium (pH 7) and
its respective (b) loading scatter plot with RT and m/z of some of those metabolites. For the same
group (Scaber vs SV-HUC-1), (c) Q2 distribution and (d) ROC plot of true and permuted classes
obtained by Monte Carlo cross validation are represented, as well.
PCA-X and PLS-DA models were also applied to compare the extracellular medium
of the different cancer lines according to grade (figure 7) and to subtype (figure 8), and
their respective R2X, R2Y and Q2 values for PLS-DA models are also presented.
Regarding the overall models presented in figures 5b, 5d, 5f, 7b and 8b, MCCV
results (Table 2) show that the prediction accuracy of the PLS-DA models was excellent
with a classification rate ranging from 96% to 100% depending on the comparison. For
instance, the PLS-DA model presented in figure 5c (Scaber vs SV-HUC-1) has a
classification rate of 97%. Besides, calculation of permuted models enables the
recognition of the groups separation observed in the PLS-DA models (figures 5, 7 and 8)
as significant since 100% of the Q2 values obtained by permutation were inferior than the
original Q2 distribution (example of figures 6c and 6d, Table 2).
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Figure 7. (a) PCA-X and (b) PLS-DA scores scatter plots obtained for the HS-SPME/GC-MS
chromatograms that compare the LG cancer cell line 5637 (n=15, ●) with HG cancer cell lines J82
(n=15, ●) and Scaber (n=15, ●) extracellular medium (pH 7). The ellipses indicate the 95%
confidence limit of the model.
Figure 8. (a) PCA-X and (b) PLS-DA scores scatter plots obtained for the HS-SPME/GC-MS
chromatograms that compare the HG TCC cell line J82 (n=15, ●) with the HG SCC cell line Scaber
(n=15, ●) extracellular medium (pH 7). The ellipses indicate the 95% confidence limit of the model.
Table 2. MCCV parameters of true and permuted classes obtained for pH 7 when
considering GC-MS full data.
Models
True classes Permuted classes
LV Q2
CR
(%)
Sens.
(%)
Spec.
(%)
LV Q2
CR
(%)
Sens.
(%)
Spec.
(%)
GC-MS full data
5637 vs SV-HUC-1 2 0.75 96 100 93 1 -0.22 47 47 47
J82 vs SV-HUC-1 2 0.69 97 100 93 1 -0.22 49 49 49
Scaber vs SV-HUC-1 3 0.91 97 100 93 1 -0.24 49 49 48
J82&Scaber vs 5637 5 0.95 100 100 100 1 -0.29 59 80 17
J82 vs Scaber 1 0.92 100 100 100 1 -0.18 49 49 49
Note: LV – number of latent variables, Q2 – medium predictive power, CR – classification rate,
sens. – sensitivity, spec. – specificity.
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5.1.2. GC-MS analysis of the samples at pH 2
The GC-MS analysis of the samples at pH 2 consistently resulted in a total of 206
peaks, in which 107 were in common with pH 7 chromatographic peaks. Representative
full scan chromatograms of each cell line are presented with some of the most abundant
compounds, as well as the respective controls medium (figure 9).
Comparing the chromatograms from samples obtained at pH 7 and pH 2 (figures 3
and 9, respectively), it is possible to observe that altering the pH changed the VOC profile
of samples. Acidification of samples generated more chromatographic peaks and
metabolites such as 2-ethyl-1-hexanol and 4-methylbenzaldehyde became more intense
at pH 2 compared to pH 7.
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Figure 9. A. Representative full scan chromatograms obtained from the analysis of the
extracellular medium of (a) SV-HUC-1, (b) 5637, (c) J82 and (d) Scaber, at pH 2. B. Representative
full scan chromatograms obtained from the analysis of the controls medium of (a) SV-HUC-1 and
(b) 5637, J82 and Scaber, at pH 2. Legend: 1. cyclohexanol; 2. 2,6-dimethylheptan-4-one; 3. 4-
fluorobenzaldehyde (IS); 4. 2-ethyl-1-hexanol; 5. 4-methylbenzaldehyde; 6. 2-ethylhexanoic acid; 7.
octanoic acid; 8. nonanoic acid; 9. decanoic acid; 10. hexadecanal. Note: the compounds are
characterized by their IUPAC names.
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After chemometric analysis, QCs at pH 2 were also closely clustered but slightly
decentred in the PCA-X model (figure 10), compared to pH 7. As expected, a clear
separation between the culture medium of the cell lines and the controls was observed on
PC1, as well (figure 10).
Figure 10. PCA-X score scatter plot obtained for the HS-SPME/GC-MS chromatograms of all
samples at pH 2, namely medium of the controls (n=60, ●), QCs (n=8, ●) and extracellular medium
of all cell lines (n=60, ●). The ellipses indicate the 95% confidence limit of the model.
Considering the extracellular medium of the cell lines, PCA-X and PLS-DA scores
scatter plots were performed to see whether a clear separation was also evident as that
observed between pH 7 samples. Indeed, PCA-X and PLS-DA models were similar as
those obtained for pH 7 and a good separation between the extracellular medium of the
BC cell lines and the normal cell line was observed (figures 11a to 11f). Values for R2X,
R2Y and Q2 are also presented in each figure. One sample from the cell line 5637 group
was excluded from the PLS-DA model and from the following statistical analyses since it
was considered an outlier for the same reasons as those considered for the SV-HUC-1
outlier (pH 7). The method used for the identification of the metabolites responsible for the
groups separation in all comparisons, at pH 2, was identical as performed for pH 7
(VIP>1). In figures 12a and 12b, it is also illustrated an example of a PLS-DA model
(Scaber vs SV-HUC-1) and its corresponding loading scatter plot, respectively. The
metabolites’ variations were also verified by using boxplots performed on Graphpad and
by determining the % of variation and effect size values. The Q2 distribution and ROC plot
of true and permuted classes obtained by MCCV (Table 3) for the PLS-DA model
represented in figure 12a are also presented in figures 12c and 12d, respectively.
t[2
]
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Figure 11. (a), (c) and (e) PCA-X and (b), (d) and (f) PLS-DA scores scatter plots obtained for the
HS-SPME/GC-MS chromatograms of the normal cell line (SV-HUC-1, n=15, ●) and the cancer cell
lines 5637 (n=14, ●), J82 (n=15, ●) and Scaber (n=15, ●) extracellular medium (pH 2), respectively.
The ellipses indicate the 95% confidence limit of the model.
t[2
]
(a)
t[2
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(b)
R2X=0.659 R2Y=0.997 Q2=0.990
t[2
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R2X=0.690 R2Y=0.994 Q2=0.988
t[2
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(e)
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(f)
R2X=0.741 R2Y=0.995 Q2=0.993
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Figure 12. Example of the method used for the identification of the most significant metabolites
represented by (a) PLS-DA score scatter plot obtained for the HS-SPME/GC-MS chromatograms
of the normal cell line (SV-HUC-1, n=15, ●) and Scaber (n=15, ●) extracellular medium (pH 2) and
its respective (b) loading scatter plot with RT and m/z of some of those metabolites. For the same
group (Scaber vs SV-HUC-1), (c) Q2 distribution and (d) ROC plot of true and permuted classes
obtained by Monte Carlo cross validation are represented, as well.
PCA-X and PLS-DA models were also applied to compare the extracellular medium
of the different cancer cell lines according to grade (figure 13) and to subtype (figure 14),
at pH 2. The respective R2X, R2Y and Q2 values for PLS-DA models are presented, as
well.
Regarding the overall models presented in figures 11b, 11d, 11f, 13b and 14b, MCCV
results (Table 3) show that the prediction accuracy of the PLS-DA models was excellent
with an average classification rate of 100% for all comparisons, which is slightly better
than those obtained for pH 7. In addition, calculation of permuted models at pH 2 also
enables the recognition of the groups separations observed in the PLS-DA models
(figures 11, 13 and 14) as significant since 100% of the Q2 values obtained by permutation
were, again, inferior to the original Q2 distribution (example of figures 12c and 12d, Table
3).
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Figure 13. (a) PCA-X and (b) PLS-DA scores scatter plots obtained for the HS-SPME/GC-MS
chromatograms that compare the LG cancer cell line 5637 (n=14, ●) with HG cancer cell lines J82
(n=15, ●) and Scaber (n=15, ●) extracellular medium (pH 2). The ellipses indicate the 95%
confidence limit of the model.
Figure 14. (a) PCA-X and (b) PLS-DA scores scatter plots obtained for the HS-SPME/GC-MS
chromatograms that compare the HG TCC cell line J82 (n=15, ●) with HG SCC cell line Scaber
(n=15, ●) extracellular medium (pH 2). The ellipses indicate the 95% confidence limit of the model.
Table 3. MCCV parameters of true and permuted classes obtained for pH 2 when
considering GC-MS full data.
Models
True classes Permuted classes
LV Q2
CR
(%)
Sens.
(%)
Spec.
(%)
LV Q2
CR
(%)
Sens.
(%)
Spec.
(%)
GC-MS full data
5637 vs SV HUC-1 1 0.99 100 100 100 1 -0.19 46 42 50
J82 vs SV HUC-1 1 0.98 100 100 100 1 -0.20 49 49 49
Scaber vs SV HUC-1 4 0.98 100 100 100 1 -0.19 49 48 49
J82&Scaber vs 5637 4 0.95 100 100 100 1 -0.17 60 80 19
J82 vs Scaber 2 0.97 100 100 100 1 -0.23 50 49 50
Note: LV – number of latent variables, Q2 – medium predictive power, CR – classification rate,
sens. – sensitivity, spec. – specificity.
(a) (b)
R2X=0.493 R2Y=0.879 Q2=0.869
(a)
R2X=0.579 R2Y=0.978 Q2=0.970
(b)
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5.2. Untargeted approach: selection of the discriminative metabolites
After statistical analysis, several compounds from pH 7 samples analysis revealed
to be significant in discriminating the cell lines culture medium, whereas, from the pH 2
analysis, the total of number of discriminant metabolites was lower, being most of them in
common with pH 7 metabolites. The general characteristics of these metabolites, such as
retention time (RT), characteristic ions (m/z), HMDB identification and matrices or cellular
locations where they have been previously found are summarized in Supplementary Table
S2 (Appendix) for both pHs.
5.2.1. Discriminative VOCs extracted at pH 7
5.2.1.1. Cancer versus normal cell lines extracellular medium
By studying the loading scatter plots and considering a VIP>1, it was possible to
discover which compounds were responsible for the separation of each cancer cell line
from the normal cell line extracellular medium. The analysis resulted in a total of 68 VOCs
significantly altered (Table 4). Of those 68 VOCs, only 21 appeared altered in the three
cancer cell lines, such as isopentanol, cyclohexanol, 4-methylheptan-2-one,
benzaldehyde, 4-methylnonane, 2-nonanone, dodecane and tetradecane, which were
increased in cancer cells medium, and 2-ethyl-1-hexanol, octanol and 2-phenylpropanol,
which were decreased in cancer cells medium compared to SV-HUC-1 medium. However,
1,3-dimethylbenzene, acetophenone, 1-phenoxypropan-2-ol and 2-pentadecanone,
despite being altered in the three cancer cells medium compared to the normal one, were
observed to have a different trend of alteration among cancer cells. For instance, 1,3-
dimethylbenzene and 1-phenoxypropan-2-ol were found increased and decreased,
respectively, in 5637 and J82 compared to SV-HUC-1 culture medium, whereas in Scaber
culture medium the variation is inverse, which may be related to the subtype of BC as
5637 and J82 are TCC and Scaber is SCC. Acetophenone was increased in 5637 but
decreased in J82 and Scaber culture medium compared to the normal cells, which in this
case, this difference between BC cells might be related to the grade of cancer.
Interestingly, 2-pentadecanone was found decreased in 5637 and Scaber but augmented
in J82 culture medium, which may be a characteristic of J82 cell line (high-grade TCC).
The remaining 47 metabolites were altered either in two of the cancer cells or
altered in only one of the cancer cells. VOCs that only appeared significantly altered in
5637 and J82 culture medium compared with SV-HUC-1 culture medium may be an
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indicative of the BC subtype TCC. Among those compounds, ethylbenzene, 6-
methylheptan-2-one, 1,2,4-trimethylbenzene and two unidentified metabolites (unknowns
9 and 17) were increased and 2-tridecanone and unknown 7 were decreased in the
extracellular medium of TCC cells. Additionally, 3-ethyloctane and nonanal were
increased in 5637 but decreased in J82 compared to SV-HUC-1 culture medium, which
can also correlate with low or high-grade TCC.
There were also some compounds that were found statistically different only in J82
and Scaber culture medium compared with the normal cell one, but were not significantly
altered in 5637 culture medium, evidencing again the influence of cancer grade.
Cyclohexanone, benzyl alcohol, menthol, α-terpineol, 2-hydroxy-2-methyl-1-phenylpropan-
1-one and unknown 21 were diminished, whereas unknowns 4 and 16 were augmented in
HG cancer cells culture medium (Table 4). One of the VOCs, phenol, was decreased in
J82 but augmented in Scaber culture medium compared to SV-HUC-1, so the subtype of
BC may be influencing the difference.
Concerning 5637 extracellular medium, methyl isobutyl ketone, styrene, 2,6-
dimethylnonane and naphthalene were increased whereas the unknowns 13 and 22-24
were decreased compared to SV-HUC-1 extracellular medium. In turn, 1,2-
dimethylbenzene, 2-undecanone and the unknown 19 were increased and 2-methyl-2-
butanol was decreased in J82 extracellular medium compared to SV-HUC-1 extracellular
medium (Table 4). As for Scaber extracellular medium, 2-pentanone, 2-methyl-2-pentanol,
benzothiazole, dodecanal and 1-dodecanol were increased whereas the unknowns 10
and 26 were decreased compared to SV-HUC-1 extracellular medium (Table 4). These
VOCs are important as they may be specific signatures of each cell line. Interestingly, 2-
pentadecanone was the only compound that was not present in the controls medium,
which suggests that its origin arises undoubtedly from the bladder cells metabolism.
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The PCA-X and PLS-DA scores scatter plots that were performed considering the
metabolites identified as significantly discriminative remained almost unchanged, with a
clear separation between cancer cell lines and the normal cell line (figures 15a to 15f).
R2X, R2Y and Q2 values became slightly better as well (except for Scaber versus SV-
HUC-1). Besides, MCCV results (Table 5) of the PLS-DA models in figures 15b, d and f
confirm the robustness of the metabolic signature for each cancer cell line compared with
the normal one, since the classification rate is 100% for all comparisons and Q2 values
obtained for the permuted classes are lower than the original Q2 values.
Figure 15. (a), (c) and (e) PCA-X and (b), (d) and (f) PLS-DA scores scatter plots obtained for the
normal cell line (SV-HUC-1, n=14, ●) and the cancer cell lines 5637 (n=15, ●), J82 (n=15, ●) and
Scaber (n=15, ●) extracellular medium, respectively, considering the discriminative metabolites
only, at pH 7. The ellipses indicate the 95% confidence limit of the model.
t[2
]
(a)
t[2
]
R2X=0.723 R2Y=0.987 Q2=0.979
(b)
t[2
]
(c)
t[2
]
R2X=0.655 R2Y=0.989 Q2=0.983
(d)
t[2
]
(e)
t[2
]
R2X=0.720 R2Y=0.982 Q2=0.976
(f)
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Boxplots of some of the most important metabolites responsible for the separation of
the cancer cell lines and SV-HUC-1 are also represented (figure 16).
a) 4-methylheptan-2-one
b) 4-methylnonane
c) 2-phenylpropan-2-ol
d) Dodecane
Figure 16. Boxplots for four VOCs found significantly altered between the normal cell line SV-HUC-
1 (n=14) and the cancer cell lines 5637 (n=15), J82 (n=15) and Scaber (n=15) extracellular
medium. p-value for a) 4-methylheptan-2-one; b) 4-methylnonane; (c) 2-phenylpropan-2-ol and (d)
dodecane is <1.00x10-4. Note: p-values are equal in all combinations.
SV-HUC-1 5637 SV-HUC-1 SV-HUC-1J82 Scaber
SV-HUC-1 5637 SV-HUC-1 SV-HUC-1J82 Scaber
SV-HUC-1 5637 SV-HUC-1 SV-HUC-1J82 Scaber
SV-HUC-1 5637 SV-HUC-1 SV-HUC-1J82 Scaber
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5.2.1.2. 5637 versus J82 and Scaber extracellular medium
A comparison between the low-grade (LG) cancer line 5637 and the high-grade
(HG) BC cell lines J82 and Scaber was also performed to investigate which metabolites
would enable the evaluation of tumour aggressiveness. A great number of metabolites
appeared as being significantly altered, such as isopentanol, cyclohexanone, benzyl
alcohol, α-terpineol, tetradecane, which were decreased in HG cancer cells medium, and
benzaldehyde, 2-ethyl-1-hexanol, octanol, 1-phenoxypropan-2-ol and γ-nonalactone,
which were augmented in HG cancer cells compared to 5637 culture medium, among
others (Table 6).
The metabolic signature found for LG BC compared to HG BC cell lines was also
confirmed by performing a PCA-X and PLS-DA scores scatter plots with the most
important metabolites (figure 17). A clear separation between the cancer lines remained,
as well as an excellent Q2 value. In table 5, it is possible to see that MCCV confirm the
robustness of the metabolic signature responsible for separating 5637 from HG cancer
cells (classification rate of 100% and Q2 values of permuted classes inferior to the original
Q2 values).
Figure 17. (a) PCA-X and (b) PLS-DA scores scatter plots obtained for the cancer cell lines 5637
(n=15, ●), J82 (n=15, ●) and Scaber (n=15, ●) extracellular medium, considering the discriminative
metabolites only, at pH 7. The ellipses indicate the 95% confidence limit of the model.
Boxplots of some of the relevant metabolites in the separation of the cancer cell
lines according to their grade are also represented (figure 18).
t[2
]
(a)
t[2
]
(b)
R2X=0.840 R2Y=0.949 Q2=0.925
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Figure 18. Boxplots for four VOCs found significantly altered between the LG cancer cell line 5637
(n=15) and the HG cancer cell lines J82 (n=15) and Scaber (n=15) extracellular medium. p-value
for a) benzyl alcohol; b) acetophenone; c) unknown 23 and (d) unknown 24 is <1.00x10-4.
5.2.1.3. J82 versus Scaber extracellular medium
The two HG BC cell lines J82 and Scaber represent different subtypes of BC (TCC
and SCC, respectively). Thus, we thought it would be worthy to compare these two cell
lines and to study the metabolites that are significantly different between them. Indeed, it
was found that 22 metabolites were also significantly altered between J82 and Scaber
(Table 6), demonstrating that different histological subtypes of BC present different VOC
profiles.
After identifying the discriminative metabolites, PCA-X and PLS-DA scores scatter
plots were performed to confirm that those metabolites were indeed responsible for the
separation of J82 and Scaber. As expected, the separation between the two cancer cell
lines remained excellent (figure 19) and that is also demonstrated by the MCCV results in
Table 5 (classification rate of 100% and Q2 values of permuted classes lower than the
original Q2 values).
a) Benzyl alcohol
LG BC HG BC
b) Acetophenone
LG BC HG BC
c) Unknown 23
LG BC HG BC
d) Unknown 24
LG BC HG BC
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Figure 19. (a) PCA-X and (b) PLS-DA scores scatter plots obtained for the cancer cell lines J82
(n=15, ●) and Scaber (n=15, ●) extracellular medium, considering the discriminative metabolites
only, at pH 7. The ellipses indicate the 95% confidence limit of the model.
Boxplots of three of the relevant metabolites in the separation of the two different BC
subtypes cell lines are also represented (figure 20).
Figure 20. Boxplots for three VOCs found significantly altered between the cancer cell lines J82
(HG TCC, n=15) and Scaber (HG SCC, n=15) extracellular medium. p-value for a) cyclohexanone;
b) acetophenone and c) 2-pentadecanone is <1.00x10-4.
Table 5. MCCV parameters of true and permuted classes obtained for pH 7 when
considering the set of discriminant VOCs with statistical relevance (p-value < 0.05).
Models
True classes Permuted classes
LV Q2
CR
(%)
Sens.
(%)
Spec.
(%)
LV Q2
CR
(%)
Sens.
(%)
Spec.
(%)
Set of discriminant VOCs
5637 vs SV-HUC-1 3 0.99 100 100 100 1 -0.19 47 48 49
J82 vs SV-HUC-1 3 0.99 100 100 100 1 -0.22 48 51 45
Scaber vs SV-HUC-1 1 0.97 97 100 93 1 -0.24 46 46 46
J82&Scaber vs 5637 4 0.97 100 100 100 1 -0.28 57 71 29
J82 vs Scaber 1 0.92 100 100 100 1 -0.16 49 49 50
Note: LV – number of latent variables, Q2 – medium predictive power, CR – classification rate,
sens. – sensitivity, spec. – specificity.
t[2
]
(a)
t[2
]
R2X=0.766 R2Y=0.977 Q2=0.971
(b)
a) Cyclohexanone
J82 Scaber
b) Acetophenone
J82 Scaber
c) 2-pentadecanone
J82 Scaber
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5.2.2. Discriminative VOCs extracted at pH 2
Overall, and considering all comparisons between the bladder cell lines, VOCs
extraction at pH 2 resulted in 32 discriminative metabolites, of which 24 were identical to
those extracted at pH 7 compounds and presented the same trend of change between the
cancer cell lines and the normal cell line extracellular medium (Supplementary Table S2,
Appendix). Therefore, only the eight VOCs exclusively found significantly altered at pH 2
will be considered in order to avoid repetitions, except in the PCA-X and PLS-DA models,
in which all relevant metabolites were included as part of the metabolic signature.
5.2.2.1. Cancer versus normal cell lines extracellular medium
For the comparison between cancer cell lines and SV-HUC-1 culture medium, seven
of the eight exclusive VOCs of pH 2 extraction were found significantly altered; however,
not in all cancer cell types (Table 7). For instance, there was only one VOC shared by the
three cancer cell lines, namely α-methylstyrene, whose levels were diminished in the
cancer cells compared with the normal cell line culture medium. As in pH 7 results, there
was also metabolites shared by two of the cancer cells, according to their subtype or
grade of BC. As for the subtype of BC, γ-dodecalactone and unknown 28 were increased,
and unknown 27 was decreased in both TCC cell lines culture medium compared to SV-
HUC-1 culture medium whereas in Scaber culture medium, these metabolites were not
statistically different. In turn, benzoic acid only appeared significantly diminished in the HG
cancer cells culture medium (J82 and Scaber) compared with SV-HUC-1 (Table 7). Lastly,
two pH 2 VOCs were only statistically different in Scaber, namely 2-methyl-2-heptanol and
methyl nonanoate, both decreased in Scaber culture medium compared with the normal
one, which may represent 2 specific VOCs of the SCC cell line.
Noteworthy, and likewise 2-pentadecanone, γ-dodecalactone was not found in
controls medium, being only present in all bladder cell lines culture medium, making this
VOC equally important for BC metabolic signature as 2-pentadecanone.
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In order to ascertain the robustness of the metabolic signature at pH 2 for the
separation of cancer cells and the normal cell, PCA-X and PLS-DA scores scatter plots
were performed considering only the set of significant metabolites. Indeed, the separation
between cancer cells and the normal cell line extracellular medium was evident (figures
21a to 21f). MCCV results of the PLS-DA models (figures 21b, d and f) confirm the
robustness of the metabolic signature for each cancer cell line compared with the normal
one, since the classification rate is 100% (except for 5637 versus SV-HUC-1). Besides,
the Q2 values obtained for the permuted classes are inferior to the original Q2 values
(Table 8).
Figure 21. (a), (c) and (e) PCA-X and (b), (d) and (f) PLS-DA scores scatter plots obtained for the
normal cell line (SV-HUC-1, n=15, ●) and the cancer cell lines 5637 (n=14, ●), J82 (n=15, ●) and
Scaber (n=15, ●) extracellular medium, considering the discriminative metabolites only, at pH 2.
The ellipses indicate the 95% confidence limit of the model.
t[2
]
(a)
R2X=0.796 R2Y=0.938 Q2=0.914
t[2
]
(b)
t[2
]
(c)
t[2
]
(d)
R2X=0.826 R2Y=0.941 Q2=0.917
t[2
]
(e)
t[2
]
(f)
R2X=0.809 R2Y=0.958 Q2=0.945
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Similarly to pH 7, boxplots of three important pH 2 metabolites responsible for the
separation of the cancer cell lines and SV-HUC-1 are also represented (figure 22).
a) α-Methylstyrene
b) Benzoic acid
c) γ-Dodecalactone
Figure 22. Boxplots for three of the VOCs found significantly altered between the normal cell line
SV-HUC-1 (n=14) and the cancer cell lines 5637 (n=15), J82 (n=15) and Scaber (n=15)
extracellular medium. p-value for a) α-methylstyrene; b) benzoic acid and c) γ-dodecalactone is
<1.00x10-4. Note: p-values are equal in all combinations, except for α-methylstyrene, which is
1.50x10-3 for SV-HUC-1 versus 5637.
An example of a correlation network analysis of VOCs significantly altered between
the extracellular medium of the cancer cell line J82 and the normal one (SV-HUC-1) was
performed (figure 23). This comparison was chosen since J82 represents a higher-grade
BC, thus the differences in VOCs levels between this cell line and SV-HUC-1 would be
more relevant, and it represents the most common form of BC (TCC). VOCs extracted at
both pHs were considered in the correlation network analysis. The explanation of the
network obtained for this comparison will be further elucidated in the discussion.
SV-HUC-1 5637 SV-HUC-1 SV-HUC-1J82 Scaber
SV-HUC-1 SV-HUC-1J82 Scaber
SV-HUC-1 J82SV-HUC-1 5637
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Figure 23. Correlation network of VOCs selected as important for discrimination of the cancer cell
line J82 from the normal cell line SV-HUC-1 in pH 7 and 2, based on Spearman’s correlation
coefficients (r 0.8 and p < 0.01). Node size denotes the effect size value of J82 in relation to
SV-HUC-1. Node colours indicate direction of effect size with red for decrease and green for
increase. Dark red and blue lines correspond to positive and negative correlations, respectively.
For some VOCs, no correlations were found according to the threshold r 0.8 and p < 0.01, and
hence are not represented in this map, namely 2-methyl-2-butanol, cyclohexanol, unknown 3,
benzyl alcohol, unknown 7, 1-octanol, nonanal, menthol, 1-phenoxypropan-2-ol, 2-undecanone and
unknown 19. Compound identification: 1. Isopentanol, 2. ethylbenzene, 3. 1,3-dimethylbenzene, 4.
1,2-dimethylbenzene, 5. cyclohexanone, 6. 4-methylheptan-2-one, 7. 6-methylheptan-2-one, 8.
benzaldehyde, 9. 4-methylnonane, 10. 3-ethyloctane, 11. phenol, 12. unknown 4, 13. 1,2,4-
trimethylbenzene, 14. unknown 5, 15. 2-ethyl-1-hexanol, 16. unknown 8, 17. unknown 9, 18.
acetophenone, 19. unknown 11, 20. 2-phenyl-2-propanol, 2. 2-nonanone, 22. unknown 14, 23. -
terpineol, 24. dodecane, 25. unknown 15, 26. 2-hydroxy-2-methyl-1-phenylpropan-1-one, 27.
unknown 16, 28. unknown 17, 29. tetradecane, 30. unknown 21, 31. 2-tridecanone, 32. 2-
pentadecanone, 33. -methylstyrene, 34. benzoic acid, 35. unknown 27, 36. unknown 28, 37. γ-
dodecalactone.
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5.2.2.2. 5637 versus J82 and Scaber extracellular medium
Comparing 5637 (LG BC) with J82 and Scaber (HG BC), only four of the eight pH 2
exclusive VOCs were significantly altered. Levels of α-methylstyrene and γ-dodecalactone
were diminished whereas (2E,4E)-deca-2,4-dienal and the unknown 28 were augmented
in HG cancer cell culture medium (Table 9).
PCA-X and PLS-DA models considering the discriminative metabolites for LG BC
and HG BC comparison can be observed in figure 24. As expected, separation of the cell
lines was excellent. MCCV results confirm the robustness of the PLS-DA model since the
set of discriminant metabolites gives a classification rate of 100% and Q2 values obtained
for the permuted classes are lower than those of the original distribution (Table 8).
Figure 24. (a) PCA-X and (b) PLS-DA scores scatter plots obtained for the cancer cell lines 5637
(n=14, ●), J82 (n=15, ●) and Scaber (n=15, ●) extracellular medium, considering the discriminative
metabolites only. The ellipses indicate the 95% confidence limit of the model.
Boxplots of two important and exclusive metabolites of pH 2 extraction responsible
for the separation of the LG BC cell line and HG BC cells can be seen as well (figure 25).
Figure 25. Boxplots for two of the VOCs found significantly altered between the LG cancer cell line
5637 (n=15) and the HG cancer cell lines J82 (n=15) and Scaber (n=15) extracellular medium. p-
value for a) α-methylstyrene and b) unknown 28 is 5.00x10-4 and 6.00x10-4, respectively.
(a) (b)
R2X=866 R2Y=0.899 Q2=0.868
a) α-Methylstyrene
LG BC HG BC
b) Unknown 28
LG BC HG BC
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5.2.2.3. J82 versus Scaber extracellular medium
The comparison of J82 and Scaber extracellular medium, at pH 2, resulted in four
significantly altered VOCs, in addition to those identical with pH 7. These include benzoic
acid, (2E,4E)-deca-2,4-dienal and γ-dodecalactone, which were all augmented in the
extracellular medium of J82 compared to the one of Scaber (Table 9).
Additionally, PCA-X and PLS-DA models were also performed to confirm the
robustness of the metabolic profile after identification of the most important metabolites
(figure 26). The cancer cell lines remained clearly separated in both statistical models.
MCCV results show that PLS-DA model considering the set of discriminative metabolites
gives a classification rate of 100% and Q2 values obtained for the permuted classes are
lower than those of the original distribution (Table 8), confirming that the selected
metabolites are responsible for the separation.
Figure 26. (a) PCA-X and (b) PLS-DA scores scatter plots obtained for the cancer cell lines J82
(n=15, ●) and Scaber (n=15, ●) extracellular medium, considering the discriminative metabolites
only. The ellipses indicate the 95% confidence limit of the model.
Boxplots of three relevant pH 2 VOCs in the separation of J82 and Scaber are also
represented (figure 27).
t[2
]
(a)
R2X=918 R2Y=0.975 Q2=0.947
t[2
]
(b)
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Figure 27. Boxplots for three VOCs found significantly altered between the cancer cell lines J82
(HG TCC, n=15) and Scaber (HG SCC, n=15) extracellular medium. p-value for a) benzoic acid; b)
(2E,4E)-deca-2,4-dienal and c) γ-dodecalactone is <1.00x10-4.
Table 8. MCCV parameters of true and permuted classes obtained for pH 2 when
considering the set of discriminant VOCs with statistical relevance (p-value < 0.05).
Models
True classes Permuted classes
LV Q2
CR
(%)
Sens.
(%)
Spec.
(%)
LV Q2
CR
(%)
Sens.
(%)
Spec.
(%)
Set of discriminant VOCs
5637 vs SV HUC-1 1 0.95 90 100 81 1 -0.22 49 45 52
J82 vs SV HUC-1 1 0.95 100 100 100 1 -0.23 49 49 49
Scaber vs SV HUC-1 2 0.97 100 100 100 1 -0.22 47 47 47
J82&Scaber vs 5637 2 0.94 100 100 100 1 -0.21 61 84 13
J82 vs Scaber 1 0.96 100 100 100 1 -0.21 49 49 49
Note: LV – number of latent variables, Q2 – medium predictive power, CR – classification rate,
sens. – sensitivity, spec. – specificity.
J82 Scaber
a) Benzoic acid
J82 Scaber
b) (2E,4E)-deca-2,4-dienal c) γ-Dodecalactone
J82 Scaber
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6. DISCUSSION
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Despite the potential of VOCs in discriminating cancer from non-cancer samples
(98, 106, 118, 139-141), only one study has focused on BC volatilome (142) and few have
reported VOCs as BC discriminative metabolites (37, 84, 87, 143). Due to the scarcity of
studies investigating the BC volatilome, we decided to investigate the characteristic VOC
signature of this cancer by studying the extracellular medium of three BC cell lines, which
offers the advantage of not suffering interferences related to different genetic and
metabolic characteristics of patients, as in the case of biological matrices, providing an
unchanged metabolic signature originated from cells directly. Besides, the study of cells
exometabolome was chosen since it is more suitable for VOCs collection than
endometabolome, in addition to greatly reflect the cellular metabolic activity through
analysis of consumed or released compounds by cells (73). Besides, VOCs released by
cancer cells can be found in samples such as breath, blood or urine, which makes volatile
metabolites appropriate candidates for the translatability to clinics (97).
This in vitro study is pivotal in investigating a VOC-biomarker panel for BC and
provides a first insight on BC volatilome, which in the future may help in the early
detection of this cancer, preferentially in a non-invasive way.
Two different pHs were evaluated, as well, so that it would be possible to determine
the optimum pH for VOCs extraction in in vitro studies. The results obtained for this
evaluation will be further explained. A considerable number of VOCs were significantly
altered in BC cell lines compared with the normal one and between cancer cell lines
themselves as well, which will also be further elucidated.
6.1. Effect of pH on the profile of VOCs released from BC culture
One of the aims of this work was to determine the optimum pH for VOCs extraction
in in vitro approaches, so that it could be applied in future studies not only in cell
metabolomics, but also in biological matrices. It is well known that alteration of the pH of
the culture medium may improve the efficiency of the analysis (97), since it affects the
metabolic profile of samples, as it is shown in the present work (figures 3 and 9). A neutral
pH (pH 7) and an acidic one (pH 2) were evaluated in this study. Noteworthy, pH 2 was
selected since acidification of urine to pH 2, being urine the best matrix to study the
metabolic alterations occurring in BC (144), proved to be the optimum extraction pH in
previous urinary VOCs studies as more metabolites were observed (118, 145). At first
sight, pH 2 analysis resulted in more chromatographic peaks as well as more intense
ones for certain compounds, such as 2-ethyl-1-hexanol and 4-methylbenzaldehyde. This
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might be due to the fact that acidification of samples causes the breakdown of chemical
bonds, which results in more compounds in their non-conjugated form, facilitating their
detection (118, 145). Moreover, acidification of the samples predominantly favoured the
formation of more acidic compounds, such as organic acids (acetic, hexanoic, heptanoic,
octanoic, nonanoic and decanoic acids), benzoic acid, methyl nonanoate and methyl
decanoate, as expected.
Nevertheless, after statistical analysis, it was observed that a greater number of
compounds from pH 7 culture medium analysis revealed as significantly altered between
cancer cell lines and the normal one, whereas, at pH 2, the number of discriminant VOCs
was lower, being most of them in common with pH 7 compounds. This suggests that
compounds extracted from acidic medium are not more relevant as biomarkers than those
extracted from neutral medium and might explain why at pH 2, where acidic compounds
are predominant over basic ones, the statistical relevant metabolites were fewer than
those obtained at pH 7. An additional explanation is that, by introducing an acidic
condition in cells culture medium samples, some important non-conjugated or pH-
sensitive compounds may have suffered chemical degradation, which hindered their
detection at pH 2.
In future works, it would be interesting to evaluate a basic pH as well, in order to
compare with pH 2 and pH 7 results and to understand if basic compounds are more
significant as BC biomarkers.
6.2. VOCs responsible for discriminating BC cells from SV-HUC-1
A variety of VOCs was found to be highly discriminative between cancer cells and
the normal cell, in both pH 2 and pH 7. Those chemical compounds include alcohols,
aldehydes, ketones, alkanes, esters, carboxylic acids and monoterpenoids. However, two
major chemical classes stand out, alcohols and ketones. In the following discussion, all
pH 7 metabolites and 8 more from pH 2 exclusive metabolites will be considered to avoid
repetitions.
Considering the promising VOCs collected at pH 7, 17 compounds were found altered
and displaying the same tendency (either increased or decreased) in all three cancer cells
culture medium (Table 4), compared with the normal cell line culture medium. These
results may suggest that identical metabolic pathways are altered in 5637, J82 and
Scaber cell lines, such as oxidative stress or inflammation processes that lead to a
common metabolic profile. From those 17 VOCs, isopentanol, cyclohexanol, 2-
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phenylpropan-2-ol, 1-phenoxypropan-2-ol, 4-methylnonane, tetradecane and
acetophenone have not been reported in other cancer types so far, whether in in vitro
studies or in biological samples, which may indicate a potential specificity towards BC. As
for the remaining VOCs, they were all found in previous cancer studies.
The alcohol 1-octanol, found at lower levels in BC cells culture medium, was found
significantly increased in the culture medium of colorectal cancer (CRC) cells SW116 and
SW480, but not in the normal cell medium (114), as opposed to the results observed in
our study. It was also found diminished in urine of CRC patients, but increased in the urine
of patients with leukaemia and lymphoma (98). In turn, 2-ethyl-1-hexanol was reported to
be significantly released by a lung cancer cell line (NCI-H2087) (146), again contrary to
what was observed for BC cell lines in this study. Furthermore, it was found elevated in
melanoma tissue compared to normal tissue (99). The ketones 4-methylheptan-2-one and
2-nonanone presented significantly higher levels in the extracellular medium of BC cell
lines. The first one was detected in urine of CRC patients (98). The second one was found
augmented in the extracellular medium of HepG2 (liver cancer cell line) (147), as
observed in this study for BC cells. Additional VOCs significantly increased in BC cells
culture medium were dodecane and benzaldehyde. Similar to the results obtained for BC,
dodecane was found elevated in the exhaled breath of lung cancer (39, 148) and CRC
patients (149), as well as in lung cancer (39) and melanoma tissues (99) compared to
healthy controls. Unlike what was observed in this study, benzaldehyde was found
decreased in the extracellular medium of the liver cancer cell line HepG2 (147), which
would make benzaldehyde release a characteristic of BC cells. However, it was found at
higher levels in lung cancer tissue and in exhaled breath of lung cancer patients (39), and
two other studies have described benzaldehyde as a potential biomarker for lung cancer
diagnosis (150, 151).
Acetophenone, 1-phenoxypropan-2-ol, 1,3-dimethylbenzene and 2-pentadecanone
were significantly altered in the three BC cell lines medium compared to the normal one,
but in a different fashion. For instance, 1,3-dimethylbenzene and 1-phenoxypropan-2-ol
were found augmented and diminished, respectively, in 5637 and J82 culture medium
compared to Scaber and SV-HUC-1, which suggests metabolic differences between TCC
and SCC BC. Previous studies reporting 1,3-dimethylbenzene were contradictory as this
volatile was found either diminished (103) or increased (152) in exhaled breath of CRC
patients. Acetophenone was found increased in 5637 but decreased in J82 and Scaber
extracellular medium compared to the normal one, evidencing the influence of BC grade
in its metabolism. Moreover, 2-pentadecanone was found increased in J82 but decreased
in 5637, Scaber and SV-HUC-1 culture medium, making this metabolite augmentation
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specific for HG TCC. In fact, this ketone was not found in controls medium (without cells),
which means its origin is cellular. This makes 2-pentadecanone one of the most important
and potential metabolite of BC metabolic signature. Nevertheless, two other in vitro
studies have reported 2-pentadecanone. In one of the studies, it was observed that this
VOC was highly released by lung cancer cells (A549, NCI-H446 and SK-MES-1), whereas
in the normal cell (BEAS-2B) culture medium this compound was not found (122); in the
other study, 2-pentadecanone was highly released by the CRC cell line SW480 (114), as
well. Hence, 2-pentadecanone might be a potential biomarker but as part of a metabolite
panel due to possible lack of specificity towards BC.
Additionally, some unidentified compounds were also significantly altered in cancer
cells and, consequently, they are relevant in discriminating cancer from normal samples.
For this reason, an attempt to identify those unknown VOCs would be important in future
works with the help of standard chemicals.
The metabolite α-methylstyrene (aromatic compound) extracted at pH 2 was
significantly decreased in all cancer cell lines culture medium compared to SV-HUC-1
medium (Table 7). This metabolite might also be a good candidate as BC biomarker
since, to date, it has not been found altered in other diseases metabolomic studies.
In general, VOCs belonging to ketones, alkanes and aldehydes chemical classes
were highly released by BC cell lines whereas alcohols were significantly decreased in BC
cells extracellular medium, compared to the normal cell line medium. These results may
be related with either the synthesis of fatty acids for membrane formation or β-oxidation of
fatty acids for energy production, amino acids metabolism, oxidative stress and
inflammation processes (147, 153, 154). For instance, one can hypothesise that 1-octanol
may be associated with the synthesis of a medium-chain fatty acid, namely caprylic acid
(C8:0), as 2-ethylhexanol may originate 2-ethylhexanoic acid (147); however, this requires
further investigation since the source of alcohols remains uncertain. The presence of
ketones in the extracellular medium of cancer cells may result from β-oxidation of
branched-chain fatty acids (147, 155). The metabolism of the branched chain fatty acid
nonanoic acid may result in 2-nonanone production in BC cells, as well as the metabolism
of C15:0 long-chain fatty acids may originate 2-pentadecanone in J82 cells, analogous to
what was demonstrated in the case of other ketone (3-heptanone) (155). It is known that
cancer cells rely on β-oxidation as an alternative pathway to generate sufficient energy to
sustain their higher energetic demands (156). Indeed, increase in fatty acid β-oxidation
have already been associated to several cancer types, including BC (22, 87, 90, 157, 158)
and others such as those of the kidney (159-161), prostate (162, 163) and pancreas
(164). In an attempt to correlate the decrease in alcohols levels and the increase in
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ketones, the substrates that lead to ketone formation may, in turn, be products of their
respective alcohol metabolism (147), but, again, further investigation is required.
Regarding simple alkanes (such as dodecane and tetradecane) and benzaldehyde, it has
been described that they result from lipid peroxidation and their levels increase during
inflammation and oxidative stress caused by an increase of ROS levels (98, 165-167), a
hallmark of cancer. The higher oxidative stress status of cancer cells may explain the
higher levels of alkanes and benzaldehyde released by BC cells in this study. Indeed,
aldehydes are known biomarkers of oxidative stress and tissue damage (168, 169), which
makes them good possibilities as cancer diagnosis biomarkers. The source of 1,3-
dimethylbenzene or α-methylstyrene is unclear. Hence, a better understanding of the
mechanisms that originate these metabolites is needed.
Some metabolites were also found significantly altered in only one of the cancer cell
lines medium compared to SV-HUC-1 (Tables 4 and 7), suggesting a specificity according
to the cell type characteristics and metabolic needs. Additionally, other VOCs exhibited
significant differences in TCC cell lines culture medium (5637 and J82) compared to SV-
HUC-1 but not in Scaber culture medium, which evidences metabolic differences between
BC subtypes. Other VOCs were only statistically different in J82 and Scaber (HG BC)
culture medium compared to SV-HUC-1 but not in 5637 (LG BC), emphasizing that
metabolism changes as cells develop from lower grades to higher grades of cancer. Each
cell line characteristic VOCs, which will be further elucidated, are also important because
they may aid in the diagnosis of BC according to grade and subtype.
Regarding these results, the panel of common VOCs should be considered as a
primary BC-biomarker panel for the detection of this cancer. For a more specific
diagnosis, in terms of grade or even subtype, a more precise VOC panel should be
employed, which will be discussed below.
6.2.1. Network analysis of the important VOCs discriminating the cell lines
J82 and SV-HUC-1
A network analysis considering the VOCs identified as important in the
discrimination of the cancer cell line J82 and the normal one (SV-HUC-1) was performed
(figure 23) in order to get a better understanding of how VOCs would correlate and to help
evaluating which are the most important VOCs to be included in BC biomarker panel. The
comparison between the volatile exometabolome of J82 and SV-HUC-1 was chosen
because as J82 is HG BC cell, the metabolic differences would be more significant.
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Besides, J82 represents the most common subtype of BC, namely TCC, so it would be
more relevant to further study the possible correlations between the altered metabolites.
For these reasons, we thought it would be more interesting to carry out a network analysis
of the relevant VOCs for this comparison. Of note, compounds collected at both pHs were
included.
Firstly, it is quite noticeable that all benzene containing compounds are correlated
with each other solely and, interestingly, 6-methylheptan-2-one correlates with
ethylbenzene, 1,2-dimethylbenzene and 1,3-dimethylbenzene as well. All these VOCs are
increased in J82 culture medium (Table 4) and they are positively correlated (red lines),
which means that they all increase when one of the compounds increase. For instance, as
ethylbenzene increases, the other 4 VOCs tend to increase as well.
Secondly, it is possible to observe a major network correlating most VOCs. For
instance, as phenol decreases, acetophenone, cyclohexanone and unknown 21 also
decrease as opposed to the unknowns 4, 8 and 9, which increase. Other relevant
correlations involve 2-pentadecanone and γ-dodecalactone, the two VOCs that were
absent in controls medium. Regarding 2-pentadecanone, it is correlated positively with
benzaldehyde, 4-methylheptan-2-one, tetradecane and the unknowns 14 and 17, meaning
that all increase as 2-pentadecanone increases. In turn, as γ-dodecalactone increases,
the unknowns 14, 17 and 28 increase as well, in contrary to α-terpineol, benzoic acid, 2-
tridecanone, 2-phenyl-2-propanol and isopentanol, whose levels diminish with the
increase of γ-dodecalactone in J82 culture medium.
Moreover, VOCs with the highest differences (greater node size) are γ-
dodecalactone, dodecane and 2-pentadecanone, whose levels were significantly
increased in J82 culture medium, and phenol, 2-tridecanone, cyclohexanone and the
unknowns 21 and 27, whose levels were significantly decreased in J82 culture medium.
The node size depends on the effect size value, hence metabolites represented by the
biggest nodes are associated with higher effect size values, as confirmed in tables 4 and
7. As for the others VOCs, the magnitude of change lessens as the node size diminishes.
For instance, 3-ethyloctane, 2-ethyl-1-hexanol, 1,2,4-trimethylbenzene, 2-hydroxy-2-
methyl-1-phenylpropan-1-one and the unknowns 16 and 17 have the smallest node sizes,
suggesting that these compounds are less relevant in the discrimination of J82 from SV-
HUC-1.
In conclusion, it is possible to infer that the correlations observed between the
relevant volatiles, that resulted from the comparison of J82 and SV-HUC-1 culture
medium, suggests a proximity on the metabolic pathways in which they are involved.
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6.3. Potential discriminative VOCs of low-grade and high-grade BC
A more specific study was performed comparing the LG cell line 5637 and those of
HG cancer (J82 and Scaber) in order to investigate volatiles responsible for the separation
of these cell lines. Indeed, 42 metabolites obtained from pH 7 extraction and 18 from pH 2
extraction were found significantly altered, of which 14 were in common at both pHs.
Considering pH 7 results, at which more metabolites were found, the identified
VOCs were mostly decreased in the extracellular medium of HG cancer cell lines (Table
6), suggesting either a higher consumption or lower production and subsequent release
by both HG cancer cells compared to 5637. As for the VOCs found elevated in HG cancer
cells culture medium, those with a more significant variation were benzaldehyde, 2-ethyl-
1-hexanol, 1-phenoxypropan-2-ol, γ-nonalactone (cyclic ester), geranylacetone (acyclic
monoterpenoid) and five unknown compounds. A possible explanation for the increase of
these VOCs relies on the differences between the cells in metabolizing such compounds.
From the previous comparisons (BC cells versus SV-HUC-1), it was possible to
identify a few VOCs that were only significantly altered in HG cancer cells culture medium
compared with SV-HUC-1 culture medium, and they show the same trend of change when
compared with 5637 culture medium. This suggests that the levels of those compounds
change in a grade-dependent manner. Such VOCs are cyclohexanone, acetophenone, 2-
hydroxy-2-methyl-1-phenylpropan-1-one, benzyl alcohol, menthol and α-terpineol, all at
lower levels in HG BC (J82 and Scaber) culture medium. Apart from cyclohexanone and
benzyl alcohol, none of these VOCs were reported as potential biomarkers in other
cancers, suggestive of specificity towards BC. Cyclohexanone levels were found
significantly higher in exhaled breath of CRC patients (149). Benzyl alcohol was also
found diminished in another BC cell line (HUC T-2) culture medium compared to the
normal cell line (SV-HUC-1) culture medium, but no cancer-association was made (143).
In contrast to BC cells, melanoma cancer cells seem to highly release benzyl alcohol
compared to normal cells (120), suggesting that cells of different cancer types present
distinct metabolic needs.
The rest of the most significantly decreased volatiles in HG cancer cells extracellular
medium include 6 unidentified VOCs, isopentanol, 2-methylpentan-1-ol, cyclohexanol, 2-
phenylpropan-2-ol, methyl isobutyl ketone, 1,3-dimethylbenzene, styrene, 4-
methylnonane, 3-ethyloctane, dodecane, tetradecane and nonanal. From these
compounds, methyl isobutyl ketone, 1,3-dimethylbenzene, styrene, dodecane and
nonanal were already reported as significantly changed in previous in vitro (39, 107, 170),
ex vivo tissues (39) and exhaled breath cancer studies (39, 103, 149, 152, 167, 168, 171,
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172). Despite lacking specificity towards BC, these relevant VOCs together with the ones
possibly BC-specific, compose a potential panel of BC biomarkers that may distinguish
whether it is LG or HG cancer.
Unfortunately, as far as we know, no study has investigated alterations in VOCs in
earlier stages of BC compared with advanced stages that could help understand these
results. Nevertheless, it is possible to conclude that HG cancer cells have different
metabolic needs compared with LG cancer cells since different levels of VOCs were
observed between those cells. It is known that as tumours progress and develop to more
advanced stages, energetic demands of cancer cells increase in order to support DNA
replication, protein synthesis and production of new components (such as those for
membrane formation) so that the relentless growth and proliferation continues. Energy
production is also essential for cancer cells to survive in more hostile conditions (e.g.
under oxidative stress) and also to be able to migrate and adapt in other tissues
(originating metastases) (30, 173). Therefore, metabolic pathways, and consequently,
metabolites levels, vary in different grade cancer cells (30). Despite the lack of VOCs
studies, some in vitro (36, 174, 175), serum (46, 88) and urinary (45, 158) studies have
described metabolic alterations between LG BC and HG BC. In general, it was observed
alterations in glycolysis and pyruvate metabolism (glucose and pyruvate decreased in HG
cancer cells) (88, 175), in the TCA cycle (45), metabolism of amino acids (most found
decreased in HG BC) (36, 46, 88) and fatty acids (particularly elevated levels of carnitines
in HG BC) (45, 88, 158), and oxidative stress (GSH increased in HG BC) (174). This is in
agreement with the results obtained, particularly with regard to fatty acid β-oxidation for
energy production and fatty acid synthesis, important for membrane formation and cell
signalling.
Hence, the results obtained in this work demonstrate that VOCs analysis can be
useful for the discrimination of LG BC from advanced BC. This is important by the time of
diagnosis, enabling not only the possibility of BC early diagnosis, but also the stratification
of patients and monitoring of the cancer progression, which can improve the treatment
options and, consequently, enhance the survival rate.
6.4. VOCs responsible for differentiating BC subtypes
Regarding pH 7 extraction, it was also possible to observe that some VOCs
exhibited significant differences between the TCC cell line (J82) and SCC cell line
(Scaber) in the previous comparison of BC cell lines with SV-HUC-1 extracellular medium.
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This evidences that metabolic differences also vary with the subtype of BC. Indeed, those
VOCs confirmed to be altered in a subtype-dependent manner after comparing J82 and
Scaber culture medium, which were 1-phenoxypropan-2-ol and nonanal, both significantly
diminished in J82 compared with Scaber culture medium, and 1,3-dimethylbenzene,
ethylbenzene and 2-pentadecanone, highly increased in J82 culture medium (Tables 4
and 6). All these VOCs were previously found in other cancer studies (103, 109, 114, 122,
152, 167, 168, 170, 171, 176), except for 1-phenoxypropan-2-ol. Interestingly,
ethylbenzene was already found elevated in the urine of BC cancer patients (142).
Although no subtype or grade association was evaluated, it supports the result observed
in this study regarding ethylbenzene. Again, 2-pentadecanone is of major importance due
to its absence in controls medium.
Other compounds significantly altered, from pH 7 analysis, that differ between the
two BC subtypes include 1,2-dimethylbenzene, styrene, 1-phenylethanol, 1-octanol,
geranylacetone and unknown 18, all increased in J82 culture medium, and n-butyl
acetate, cyclohexanone, 4-methylheptan-2-one, phenol, acetophenone, 2-phenylpropan-
2-ol, methyl benzoate, benzothiazole and unknowns 2, 3 and 5, all decreased in J82
culture medium compared with Scaber culture medium. Among these VOCs, n-butyl
acetate, cyclohexanone, 4-methylheptan-2-one and phenol were also found altered in
other cancers. Cyclohexanone and 4-methylheptan-2-one have already been discussed
above. As for n-butyl acetate, it was reported to be highly consumed by HepG2 (liver
cancer cell line) (147) and by lung cancer cells (177, 178) due to the elevated levels of
carboxylesterases (CESs) present in those cells (179), which can be responsible for
converting n-butyl acetate into acetic acid and 1-butanol (147). Therefore, one can
theorize that similar differences exist between J82 and Scaber; however, further
investigation is required to confirm such hypothesis. To our knowledge, phenol was not
reported in previous in vitro studies, but it has already been found at lower levels in serum
(180) and urine (181) of CRC patients, and augmented in urine of breast cancer patients
compared to healthy controls (110). Phenol is an intermediate of tyrosine metabolism and
it might be either elevated or decreased depending on whether cells rely on tyrosine
metabolism to generate energy, which might explain, in part, the differences observed for
J82 and Scaber as well as in the other cancers. Altogether, this group of compounds
represent possible biomarkers to distinguish TCC from SCC BC.
Despite γ-dodecalactone being a pH 2 VOC, it also demonstrated specificity towards
TCC cells (Tables 7 and 9). Again, this metabolite is not present in controls medium,
making this compound highly relevant for the separation of BC cells.
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There are no previous studies that investigate differences in the metabolism of cells
from TCC or SCC subtypes of BC, as well, in order to make more accurate interpretations
of the results. Evidently, TCC and SCC cancer cell lines present distinct genetic
characteristics that can be associated with up- or down-regulation of different metabolic
enzymes. This leads to different metabolic reactions occurring in these two cell lines,
favouring the production or consumption of certain compounds over others. Nevertheless,
further investigation is required so that it is possible to understand the differences on the
metabolites between the two subtypes of BC. Finding and validating biomarkers that
distinguish TCC from SCC BC would be important in order to aid in the stratification of
patients according to BC subtype. In fact, in BC treatment guidelines, different therapies
are recommended for TCC and SCC patients (182), emphasizing the importance of an
accurate diagnosis that will enable patients to benefit from the best treatment as soon as
possible.
Overall, the study of bladder cells (both cancer and normal) volatilome from the
extracellular medium allowed the distinction of not only cancer from normal groups, but
also according to BC grade and subtype. This study, along with previous ones, showed
that cancer cells can noticeably change volatile consumption or production, which is
somewhat expected since cancer cells have altered metabolism. Although this study gives
new insight on BC metabolism and on potential diagnosis biomarkers, further research is
warranted to evaluate the robustness of the VOC profile and to validate the candidate
metabolites as BC biomarkers.
Unfortunately, studies on BC-related VOCs are scarce and the origin or fate of many
VOCs remains unclear, which hampers any definite conclusion to be made about the
results. Therefore, it is imperative to further investigate the BC volatilome using different
biological samples to better understand the metabolism of volatiles, whether they are
directly tumour-derived or produced as systemic responses to inflammation, necrosis (63,
64), alteration of microbiota (11, 64) or even related to external sources (including
environmental contamination (3), medication and diets (64)). This is of major importance
in the identification of specific BC-related VOCs since they could improve the diagnosis
and prognosis of this cancer.
Despite the difficulties and the scarcity of published works, the possibility of using
VOCs as cancer biomarkers is still desired due to their relatively easy sample preparation
and analysis. In BC case, the most suitable biological sample to investigate the presence
of VOCs would be urine, due to its direct contact with cancer cells and to where these
cells release the metabolites produced during their metabolic activity. Besides, urine has a
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non-invasive collection procedure, which offers another advantage in studying this matrix
in the future. Further work is needed to assess whether the VOCs found in this study may
ultimately be found in urine of cancer patients in abnormal concentrations. If so, these
volatiles can potentially be used as BC biomarkers, enabling the development of a non-
invasive, easy-to-use diagnostic tool.
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7. CONCLUSION AND FUTURE PERSPECTIVES
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Over the last years, the interest on VOC profiles and their association with
numerous diseases has increased, especially due to their non-invasive sampling
approach. Indeed, VOCs have proven to be potential diagnosis biomarkers in several
types of cancer such as those of the lung (176), breast (183), skin (120), colorectal (152)
and prostate (103), leukaemia and lymphoma (98). Regarding in vitro approaches, some
studies have also investigated potential VOC biomarkers for cancer diagnosis using
different cancer cell types and techniques, and in all of them it was observed differences
in VOCs composition between cancer and normal cell lines (39, 107, 114, 120, 121, 146,
177, 178, 183-185). Nevertheless, and to our knowledge, there are no studies on the
consumption or release of VOCs by human BC cell lines, making it more difficult to
compare the results obtained in this work with other data and make more specific
conclusions.
One of the aims of this work was to evaluate and compare the results obtained for
the extraction of VOCs at two different pHs (pH 2 and 7). Despite pH 2 analysis have
resulted in more chromatographic peaks in terms of total area, pH 7 analysis resulted in a
greater number of statistically significant altered metabolites. This suggests that acidic
compounds are not more important as biomarkers than neutral compounds in cancer cell
lines, making pH 7 the best choice for future in vitro metabolomic studies.
The overarching aim was, however, to discover a putative BC VOC profile. Indeed, it
was observed that levels of VOCs were different when comparing the exometabolomes of
BC cancer cells and the normal cell line, enabling to find:
1. A VOC biomarker panel for the early diagnosis of BC composed by 21
metabolites (isopentanol, cyclohexanol, 2-ethylhexan-1-ol, 1-octanol, 2-
phenylpropan-2-ol, 1-phenoxypropan-2-ol, 4-methylnonane, dodecane,
tetradecane, benzaldehyde, 4-methylheptan-2-one, acetophenone, 2-nonanone,
2-pentadecanone, 1,3-dimethylbenzene and 6 unknowns), at pH 7;
2. A VOC biomarker panel, at pH 7, for BC prognosis (prediction of disease
aggressiveness) composed by 34 metabolites (isopentanol, 2-methylpentan-1-ol,
cyclohexanol, 2-ethylhexan-1-ol, benzyl alcohol, 2-phenylpropan-2-ol, 1-
phenoxypropan-2-ol, methyl isobutyl ketone, cyclohexanone, acetophenone, 2-
hydroxy-2-methyl-1-phenylpropan-1-one, benzaldehyde, 1,3-dimethylbenzene,
styrene, 4-methylnonane, 3-ethyloctane, dodecane, tetradecane, nonanal,
menthol, α-terpineol, γ-nonalactone, geranylacetone and 11 unknowns);
3. A VOC biomarker panel, at pH 7, for the discrimination between two different
subtypes of BC (TCC or SCC), composed by 22 volatiles (n-butyl acetate, 1,3-
dimethylbenzene, ethylbenzene, 1,2-dimethylbenzene, styrene, cyclohexanone,
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4-methylheptan-2-one, acetophenone, 2-pentadecanone, phenol, 1-
phenylethanol, 1-octanol, 2-phenylpropan-2-ol, 1-phenoxypropan-2-ol, methyl
benzoate, nonanal, benzothiazole, geranylactenone, and 4 unknowns)
4. 2-Pentadecanone and γ-dodecalactone (an exclusive metabolite of pH 2
analysis) as particularly important metabolites since they were not found in
controls medium, making them potential candidates as biomarkers;
5. Ethylbenzene as a potentially good biomarker candidate, as well, since it has
been reported in a previous BC urinary study (142).
These results definitely establish a proof-of-concept for the in vitro prediction of BC
from VOCs analysis using HS-SPME/GC-MS technique and demonstrate the potential of
VOCs in discriminating BC cell lines from non-cancer one. Clearly, this study cannot
provide comprehensive conclusions about the results, as VOCs metabolism itself is not
yet well understood. Furthermore, it should be taken into consideration that isolated in
vitro cancer cells conditions do not reproduce those in the organism, which means that the
data obtained might differ from the data obtained in biological samples. Consequently, the
in vivo VOCs translation through analysis of human samples is mandatory so that
validation of the complete BC volatilome is achieved.
In conclusion, the results are encouraging as they demonstrate the potential of
VOCs as diagnosis and prognosis biomarkers, and their possible usefulness to detect BC
at earlier stages. In the future, it would be worthy to explore the biological and pathological
relevance of these discriminatory VOCs, as well as to attempt the identification of the
unknown VOCs with the use of standards, since these compounds significantly
contributed for the discrimination of BC cell lines.
In future studies, the possibility of employing 3D cultures rather than 2D ones is an
exciting strategy to obtain more information since they can establish biological models
more analogous to human tissues (153). Larger studies including other cancer cell types
would also be interesting to evaluate the specificity of the VOC profile obtained for BC.
Another interesting investigation is the search for volatiles in a simultaneous multiple
matrix study, which would be advantageous to expand our knowledge about VOCs
metabolism and to better compare the variations among different samples. Altogether, this
might lead to the assembly of a robust, specific BC biomarker panel that would help
conventional diagnosis methods. Urine would definitely be the best choice as the
biological sample for the search of BC volatile biomarkers and the development of a non-
invasive and relatively fast diagnostic tool, though a lot of work is still to be done.
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Supplementary Table S1. Results of protein quantification to assess the cellular density
of all bladder cell lines (cancer and normal) in each passage and triplicates.
Cell
line
Culture
passage
[protein]F1/
mg.mL-1
[protein]F2/
mg.mL-1
[protein]F3/
mg.mL-1
Median[protein]
Standard
deviation
SV-
HUC-1
6 4.31 4.63 4.36 4.43 0.14
7 5.04 5.93 5.37 5.45 0.37
8 4.72 4.79 5.15 4.89 0.19
9 5.31 4.65 5.23 5.06 0.29
10 5.86 6.26 5.24 5.79 0.42
5637
4 5.49 5.83 5.16 5.49 0.27
5 5.06 5.08 6.02 5.39 0.45
6 6.23 5.06 6.51 5.93 0.63
7 5.31 5.99 5.42 5.57 0.30
8 6.28 5.78 6.03 6.03 0.20
J82
4 5.47 4.70 4.60 4.92 0.39
5 4.93 4.66 5.40 5.00 0.31
6 4.98 4.84 5.73 5.18 0.39
7 6.12 5.14 6.18 5.81 0.48
8 4.69 5.25 5.05 5.00 0.23
Scaber
4 4.60 5.37 4.80 4.92 0.33
5 5.10 5.94 5.55 5.53 0.34
6 4.63 5.28 5.27 5.06 0.30
7 5.12 5.19 4.96 5.09 0.10
8 5.52 4.90 5.55 5.32 0.30
Note: F1, F2 and F3 represent the triplicates of each cell line passage.
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